USO DE UPADACITINIBE NO TRATAMENTO DE VITILIGO

Upadacitinib, a selective JAK1 inhibitor, effectively treats vitiligo by addressing autoimmune melanocyte destruction, improving vitiligo area scores and quality of life, with notable efficacy in daily doses of 11 mg and 22 mg, and a clear exposure-response relationship.

BR112025025141A2Pending Publication Date: 2026-11-10ABBVIE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025025141
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-11
Filing Date
2024-05-21
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There is a significant unmet need for effective and cost-effective treatments for vitiligo, a chronic autoimmune disorder characterized by skin depigmentation, as current treatments are limited and often inconvenient for long-term use, and there is a lack of systemic therapies with substantial efficacy.

Method used

Administering a therapeutically effective amount of the selective JAK1 inhibitor, upadacitinib, orally once daily to patients with vitiligo, particularly those with non-segmental vitiligo and specific vitiligo area scoring indices, to address the autoimmune destruction of melanocytes.

Benefits of technology

Upadacitinib demonstrates significant improvement in vitiligo area scoring indices and quality of life measures, with consistent efficacy across various doses, including 11 mg and 22 mg daily, showing a dose-dependent exposure-response relationship, and reducing inflammatory biomarkers associated with vitiligo.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure is directed to methods for treating vitiligo using the selective JAK1 inhibitor upadacitinib.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 68 Use of upadacitinib in the treatment of vitiligo. FIELD OF REVELATION

[001] The present disclosure relates to methods for treating vitiligo with the selective JAK1 inhibitor, upadacitinib. BACKGROUND TO THE REVELATION

[002] Upadacitinib is a selective JAK1 inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic spondyloarthritis, ulcerative colitis in adults, and atopic dermatitis.

[003] Vitiligo is a chronic autoimmune disorder affecting 0.5% to 2.0% of the population. It is characterized by skin depigmentation caused by the loss of melanocytes (Bergqvist et al., Dermatology 2020, 236:571-92; Ezzedine et al., Pigment Cell Melanoma Res 2012, 25:E1-13). Vitiligo is classified into two main forms (non-segmental or segmental) based on the distribution of lesions (Taieb et al., Pigment Cell Res 2007, 20:27-35). Studies have shown that vitiligo places a substantial burden on patients' quality of life. Patients with vitiligo incur direct costs associated with medical treatment, as well as indirect costs in the form of psychosocial effects, loss of work productivity, and loss of social and career opportunities. Consequently, there is a substantial unmet need for effective and cost-effective treatments.

[004] Vitiligo treatment remains one of the most difficult dermatological challenges. Currently, there is no cure available. There are few treatment options and, in general, they are limited to topical corticosteroids, ultraviolet B irradiation, and surgical treatment (Bergqvist et al., 2020). For reasons that include patient convenience and adherence to treatment, particularly in long-term treatment, it would be desirable to provide an effective oral therapy for the treatment of vitiligo. SUMMARY OF REVELATION Petition 870260018663, dated 27 / 02 / 2026, page 18 / 93 2 / 68

[005] The present disclosure provides methods for treating vitiligo with the selective JAK1 inhibitor, upadacitinib. The treatment methods generally comprise administering a therapeutically effective amount of upadacitinib to a patient in need thereof.

[006] In one aspect, a method of treating an adult human patient with vitiligo is provided, wherein the method comprises administering 15 mg of upadacitinib orally once daily to the patient.

[007] In some forms, the patient has non-segmental vitiligo (NSV).

[008] In some modes, the NSV is stable.

[009] In some modes, NSV is active.

[010] In some modalities, the patient has, before starting treatment, a Facial Vitiligo Area Scoring Index (F-VASI) > 0.5.

[011] In some modalities, the patient has, before starting treatment, a Total Vitiligo Area Scoring Index (T-VASI) > 5.

[012] In some modalities, the patient has not received any immunomodulatory biological therapy before starting treatment.

[013] In some modalities, the patient did not receive any topical JAK inhibitor within 12 weeks of starting treatment.

[014] In some modalities, the patient has leukotrichia in < 33% of the affected areas.

[015] In some modalities, the patient achieves F-VASI 75 within 24 weeks of starting treatment.

[016] In some modalities, the patient obtains, 36 weeks after the start of treatment, one or more of a T-VASI 50, a T-VASI 75, a T-VASI 90, Petition 870260018663, dated 27 / 02 / 2026, page 19 / 93 3 / 68 an F-VASI 50 or an F-VASI 90.

[017] In some modalities, the patient achieves T-VASI 50 in 48 weeks after the first daily administration.

[018] In some modalities, the patient achieves F-VASI 75 in 48 weeks after the first daily administration.

[019] In some modalities, the patient achieves T-VASI 50 in 52 weeks after the first daily administration.

[020] In some modalities, the patient achieves F-VASI 75 in 52 weeks after the first daily administration.

[021] In some modalities, the patient obtains an improvement in the Global Impression of Change-Overall Vitiligo (PaGIC-V) 36 weeks after the start of treatment.

[022] In some modalities, the patient obtains a score on the vitiligo noticeability scale (VNS) of much less noticeable (4) or no longer noticeable (5) 36 weeks after the start of treatment.

[023] In some modalities, the patient achieves an improvement from baseline in the vitiligo extent score (VES) 36 weeks after the start of treatment.

[024] In some modalities, the patient achieves an improvement from baseline on the Vitiligo Quality-of-Life questionnaire (VitiQoL) 36 weeks after starting treatment.

[025] In some modalities, the patient obtains a total Dermatology Life Quality Index (DLQI) score of 0 or 1 36 weeks after the start of treatment.

[026] In some modalities, the patient achieves an improvement from baseline in scores on the Hospital Anxiety and Depression Scale (HADS) 36 weeks after the start of treatment. Petition 870260018663, dated 27 / 02 / 2026, page 20 / 93 4 / 68

[027] In some modalities, the patient obtains an improvement in the time to the onset of repigmentation compared to a patient who was not treated with upadacitinib.

[028] In some modalities, the patient achieves a Physician's Global Impression of Change-Vitiligo (PhGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the start of treatment. In some modalities, the patient achieves a Patient's Global Impression of Change-Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the start of treatment. In some modalities, the patient achieves a Face-Physician Global Vitiligo Assessment (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the start of treatment.In some modalities, the patient obtains a Physician Global Vitiligo Assessment (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment. In some modalities, the patient obtains a Patient Global Vitiligo Assessment (F-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment. In some modalities, the patient obtains a Patient Global Vitiligo Assessment (T-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment.

[029] In some modalities, the patient obtains an improvement in itching or burning sensation within 36 weeks after the start of treatment.

[030] In some modalities, the method halts the progression of vitiligo within 36 weeks of starting treatment. Petition 870260018663, dated 27 / 02 / 2026, page 21 / 93 5 / 68

[031] In some modalities, the method results in a reduction from baseline in one or more vitiligo biomarkers within 36 weeks of treatment initiation. In some modalities, the biomarker is an inflammatory chemotactic protein or a T-cell activation marker. In some modalities, the biomarker is CXCL9, CXCL10, IL12B, TNFSF9, or a combination thereof.

[032] In some modalities, the patient is concurrently treated with exposure to ultraviolet light.

[033] In another aspect, a method of treating vitiligo in a human pediatric patient is provided, wherein the method comprises administering a therapeutically effective amount of upadacitinib to the pediatric patient, in which: If the pediatric patient has a body weight in the range of approximately 10 kg to less than approximately 20 kg: (i) Upadacitinib is administered twice daily at a dose of 3 mg each time (3 mg BID); or (ii) Upadacitinib is administered twice daily at a dose of 6 mg each time (6 mg BID); If the pediatric patient has a body weight in the range of approximately 20 kg to less than approximately 30 kg: (i) Upadacitinib is administered twice daily at a dose of 4 mg each time (4 mg BID); or (ii) Upadacitinib is administered twice daily at a dose of 8 mg each time (8 mg BID). and if the pediatric patient has a body weight of approximately 30 kg or more: (i) Upadacitinib is administered twice daily at a dose of 6 mg each time (6 mg BID), (ii) Upadacitinib is administered twice daily at a dose of 8 mg Petition 870260018663, dated 27 / 02 / 2026, page 22 / 93 6 / 68 each (8 mg BID), or (ii) upadacitinib is administered once daily at a dose of 15 mg (15 mg QD).

[034] In some embodiments, twice-daily administration at a dose of 3 mg of upadacitinib, twice-daily administration at a dose of 4 mg of upadacitinib, twice-daily administration at a dose of 6 mg of upadacitinib, or twice-daily administration at a dose of 8 mg of upadacitinib is performed on the pediatric patient as a stable oral pharmaceutical solution.

[035] In some embodiments, the stable oral pharmaceutical solution comprises upadacitinib, a buffer and / or a pH adjusting agent, a preservative, a sweetener and water.

[036] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml or approximately 1 mg / ml.

[037] In some embodiments, once-daily administration of a 15 mg dose of upadacitinib is given to the pediatric patient as a prolonged-release tablet.

[038] In some forms, the pediatric patient has non-segmental vitiligo (NSV).

[039] In some modes, the NSV is stable.

[040] In some modes, NSV is active.

[041] In some modalities, the pediatric patient has, before starting treatment, a Facial Vitiligo Area Score Index (F-VASI) > 0.5.

[042] In some modalities, the pediatric patient has, before starting treatment, a Total Vitiligo Area Score Index (T-VASI) > 5.

[043] In some modalities, the pediatric patient has not received any immunomodulatory biological therapy prior to starting treatment.

[044] In some modalities, the pediatric patient did not receive any Petition 870260018663, dated 27 / 02 / 2026, page 23 / 93 7 / 68 topical JAK inhibitor within 12 weeks of starting treatment.

[045] In some modalities, the pediatric patient has leukotrichia in < 33% of the affected areas.

[046] In some modalities, the pediatric patient achieves an F-VASI 75 24 weeks after starting treatment.

[047] In some modalities, the pediatric patient receives one or more of a T-VASI 50, a T-VASI 75, a TVASI 90, an F-VASI 50, or an F-VASI 90 within 36 weeks of starting treatment.

[048] In some modalities, the patient achieves T-VASI 50 in 48 weeks after the first daily administration.

[049] In some modalities, the pediatric patient achieves F-VASI 75 in 48 weeks after the first daily administration.

[050] In some modalities, the pediatric patient achieves T-VASI 50 in 52 weeks after the first daily administration.

[051] In some modalities, the pediatric patient achieves F-VASI 75 in 52 weeks after the first daily administration.

[052] In some modalities, the pediatric patient achieves an improvement in the Patient's Global Impression of Change regarding Vitiligo (PaGIC-V) at 36 weeks after the start of treatment.

[053] In some modalities, the pediatric patient obtains a score on the vitiligo perception scale (VNS) of much less noticeable (4) or no longer noticeable (5) 36 weeks after the start of treatment.

[054] In some modalities, the pediatric patient achieves an improvement from baseline in the vitiligo extent score (VES) at 36 weeks after the start of treatment.

[055] In some modalities, the pediatric patient achieves an improvement from baseline in VitiQoL 36 weeks after the start of treatment. Petition 870260018663, dated 27 / 02 / 2026, page 24 / 93 8 / 68

[056] In some modalities, the pediatric patient obtains a total score of 0 or 1 on the Dermatology Life Quality Index (DLQI) 36 weeks after the start of treatment.

[057] In some modalities, the pediatric patient achieves an improvement from baseline in Hospital Anxiety and Depression Scale (HADS) scores 36 weeks after the start of treatment.

[058] In some modalities, the pediatric patient achieves an improvement in the time to onset of repigmentation compared to a pediatric patient who was not treated with upadacitinib.

[059] In some modalities, the pediatric patient obtains an improvement in itching or burning sensation within 36 weeks after the start of treatment.

[060] In some modalities, the pediatric patient achieves a Physician Global Impression of Change regarding Vitiligo (PhGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the start of treatment. In some modalities, the pediatric patient achieves a Patient Global Impression of Change regarding Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the start of treatment. In some modalities, the pediatric patient achieves a Physician Global Assessment of Vitiligo - Face (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the start of treatment. In some modalities, the pediatric patient obtains a Physician Global Assessment of Vitiligo - Total (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment.In some modalities, the pediatric patient obtains a Patient-GPA-Face Vitiligo Global Assessment score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment. In some modalities, the pediatric patient obtains a Vitiligo Global Assessment score. Petition 870260018663, dated 27 / 02 / 2026, page 25 / 93 9 / 68 by Patient - Total (T-PaGVA) of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the start of treatment.

[061] In some modalities, the method stops the progression of vitiligo within 36 weeks after the start of treatment.

[062] In some modalities, the method results in a reduction from baseline in one or more vitiligo biomarkers within 36 weeks of treatment initiation. In some modalities, the biomarker is an inflammatory chemotactic protein or a T-cell activation marker. In some modalities, the biomarker is CXCL9, CXCL10, IL12B, TNFSF9, or a combination thereof.

[063] In some modalities, the pediatric patient is concomitantly treated with exposure to ultraviolet light. BRIEF DESCRIPTION OF THE DRAWINGS

[064] Figure 1 is a schematic illustration of a clinical study according to a non-limiting disclosure modality, as described in Example 1.

[065] Figure 2 is a graphical representation of effectiveness according to the primary trial endpoint (percentage change from baseline in FVASI at Week 24 (MMRM)) for individuals in the Example 1 clinical study.

[066] Figure 3 is a graphical representation of effectiveness according to the secondary test endpoint (proportion that obtains F-VASI 75 at Week 24 (NRI)) for individuals in the Example 1 clinical study.

[067] Figure 4 is a graphical representation of efficacy according to the secondary test endpoint (percentage change from baseline in T-VASI at Week 24 (NRI)) for individuals in the Example 1 clinical study.

[068] Figure 5A is a graphical representation of efficacy according to a secondary test endpoint (percentage change from baseline at T-VASI 50) at weeks 24 and 52 for subjects in the Example 1 clinical study. Petition 870260018663, dated 27 / 02 / 2026, page 26 / 93 10 / 68

[069] Figure 5B is a graphical representation of efficacy according to a secondary test endpoint (percentage change from baseline in F-VASI 75) at weeks 24 and 52 for subjects in the Example 1 clinical study.

[070] Figure 6A is a graphical representation of model-predicted and observed exposure response effectiveness analyses for the CFB F-VASI and CFB T-VASI test endpoints at week 24 according to Example 2.

[071] Figure 6B is a graphical representation of model-predicted and observed exposure response effectiveness analyses for the F-VASI 75 and T-VASI 50 test endpoints at week 24 according to Example 2.

[072] Figure 7A is a graphical representation of the model-predicted efficacy response rates for the F-VASI 75 trial endpoint for various doses of upadacitinib at week 24 according to Example 2.

[073] Figure 7B is a graphical representation of the model-predicted efficacy response rates for the T-VASI 50 trial endpoint for various doses of upadacitinib at week 24 according to Example 2.

[074] Figure 8A is a graphical representation of exploratory exposure-response analyses for the CFB F-VASI efficacy trial endpoint at week 52 according to Example 2.

[075] Figure 8B is a graphical representation of exploratory exposure-response analyses for the CFB T-VASI efficacy trial endpoint at week 52 according to Example 2.

[076] Figure 9A is a graphical representation of the model-predicted response rates for the F-VASI 75 test endpoint for a 15 mg dose of upadacitinib according to Example 2.

[077] Figure 9B is a graphical representation of the model-predicted response rates for the T-VASI 50 test endpoint for a 15 mg dose of upadacitinib according to Example 2. Petition 870260018663, dated 27 / 02 / 2026, page 27 / 93 11 / 68

[078] Figure 10A is a graphical representation of the % change in facial vitiligo area by Cherry 3D imaging for various doses of upadacitinib and placebo according to Example 3.

[079] Figure 10B is a graphical representation of the % change in F-VASI for various doses of upadacitinib and placebo according to Example 3.

[080] Figure 11 is a schematic illustration of a clinical study according to a non-limiting disclosure modality, as described in Example 4.

[081] Figure 12 is a graphical representation of the percentage change from baseline in F-VASI up to Week 52 according to Example 7.

[082] Figure 13 is a graphical representation of the percentage change from baseline in T-VASI up to Week 52 according to Example 7.

[083] Figure 14A is a graphical representation of the response rate for obtaining F-VASI 50 in Week 52 according to Example 7.

[084] Figure 14B is a graphical representation of the response rate for obtaining F-VASI 75 in Week 52 according to Example 7.

[085] Figure 14C is a graphical representation of the response rate for obtaining T-VASI 50 in Week 52 according to Example 7.

[086] Figure 15A is a graphical representation of the response rate for obtaining F-VASI 75 in Week 24 according to Example 7.

[087] Figure 15B is a graphical representation of the response rate for obtaining F-VASI 75 in Week 36 according to Example 7.

[088] Figure 15C is a graphical representation of the response rate for obtaining F-VASI 75 in Week 52 (imputation of non-responders while incorporating multiple imputation; NRI-MI) according to Example 7.

[089] Figure 15D is a graphical representation of the response rate for obtaining F-VASI 75 at Week 52 (AO) according to Example 7.

[090] Figure 16A is a graphical representation of the response rate for Petition 870260018663, dated 27 / 02 / 2026, page 28 / 93 12 / 68 obtaining T-VASI 50 in Week 24 according to Example 7.

[091] Figure 16B is a graphical representation of the response rate for obtaining T-VASI 50 in Week 36 according to Example 7.

[092] Figure 16C is a graphical representation of the response rate for obtaining T-VASI 50 in Week 52 (NRI-MI) according to Example 7.

[093] Figure 16D is a graphical representation of the response rate for obtaining T-VASI 50 in Week 52 (as observed; AO) according to Example 7. DETAILED DESCRIPTION OF THE REVELATION I. Definitions

[094] The section headings used in this section and the entire disclosure are not intended to be limiting.

[095] Where a numerical range is recited, each intervening number in the range is explicitly contemplated with the same degree of precision. For example, for the range 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are explicitly contemplated. Similarly, all cited ratios also include all sub-ratios encompassed by the broader ratio.

[096] The singular forms a / an and the / the include plural referents, unless the context clearly indicates otherwise.

[097] The term about refers, in general, to a range of numbers that someone versed in the technique would consider equivalent to the recited value (that is, with the same function or result). In many cases, the term about may include numbers rounded to the nearest significant digit.

[098] Unless the context requires otherwise, the terms understand, understands and understanding are used on the basis and clear understanding that they should be interpreted inclusively, and not Petition 870260018663, dated 27 / 02 / 2026, p. 29 / 93 13 / 68 exclusive, and the Applicant intends that each of these words be interpreted accordingly in the interpretation of this patent, including the claims below.

[099] The term AUC refers to the area under the curve. AUC is the definite integral of a curve that describes the change in a drug concentration in blood plasma as a function of time.

[0100] The term Cmax refers to the plasma concentration of the drug relative to Tmax, expressed herein as ng / ml, produced by oral ingestion of a single dose, or the indicated number of doses, of the dosage form or pharmaceutical composition, such as the dosage forms and compositions of the present disclosure. Unless specifically indicated, Cmax refers to the maximum observed total concentration.

[0101] The terms treatment, treatment and therapy and the like, as used herein, are intended to include therapeutic measures for a disease or disorder leading to a clinically desirable or beneficial effect, including, but not limited to, clinically significant improvement in depigmentation over a period of time.

[0102] As used herein, the term pediatric patient refers to a human patient under 18 years of age. The terms patient and individual are used interchangeably herein.

[0103] The term pharmaceutically acceptable salts refers to those salts that retain the biological efficacy and properties of free bases and that are obtained by reaction with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, or organic acids, such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, citric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, salicylic acid, lactic acid, monomalic acid, monooxalic acid, tartaric acid, such as monotartaric acid (for example, (+) or (-)-tartaric acid or mixtures thereof), amino acids (for example, (+) or (-)-amino acids or mixtures thereof) and the like. These salts can be prepared by methods known to Petition 870260018663, dated 27 / 02 / 2026, page 30 / 93 14 / 68 skilled in the art. Examples of pharmaceutically acceptable salts of upadacitinib can be found in WO 2017 / 066775, which is incorporated herein by reference in its entirety.

[0104] The term active vitiligo, as used herein, refers to vitiligo that shows new lesions or progression (increase) of existing lesions in the last 6 months; and / or the presentation of clinical subtypes indicative of vitiligo advancement (confetti-type depigmentation, trichrome pattern, Koebner phenomenon).

[0105] The term stable vitiligo, as used herein, refers to vitiligo without new lesions and / or without extension of pre-existing lesions.

[0106] The Vitiligo Area Score Index (VASI) is a qualitative tool analogous to the Psoriasis Area and Severity Index (PASI). VASI is used to assess the severity of vitiligo and / or the effectiveness of treatment. This is the current gold standard for semi-objective assessment of vitiligo and represents a composite estimate of the total area of ​​vitiligo patches and the degree of depigmentation within those patches. VASI is determined by approximating the percentage of body surface area affected, which is multiplied by the percentage degree of depigmentation in those areas. In determining the percentage of body surface area, the hand equals 1% and the thumb equals 0.1%. VASI can be called total (T-VASI) or facial (F-VASI). F-VASI includes contributions from the face, with a possible range of 0 to 3.For the purpose of evaluating the F-VASI, the facial area includes the forehead up to the original hairline, temples, around the eyes (including eyelids), nose, cheeks (middle and lateral), and around the mouth (including the chin). The face excludes the lips, ears, and scalp.

[0107] The Vitiligo Perception Scale (VNS) is a validated single-item questionnaire used in clinical trials to assess the perception of vitiligo lesions after therapy.1 The item is scored on a 5-point scale: 1 = most noticeable; 2 = as noticeable; 3 = slightly less noticeable; 4 = much less noticeable; and 5 = not noticeable. Petition 870260018663, dated 27 / 02 / 2026, p. 31 / 93 15 / 68 is more noticeable. A score of 4 or 5 represents treatment success.

[0108] The Vitiligo Quality of Life Questionnaire (VitiQoL) is a validated questionnaire used in clinical trials to assess the stigma-related impacts of vitiligo. The VitiQoL uses individual-generated social, affective, and behavioral items, prompting the individual to rate the impacts of vitiligo over the past month. Fifteen items are scored on a 7-point scale ranging from 0 (not at all) to 6 (all the time). Item scores (0 to 6) are summed to provide a total score range of 0 to 90; higher scores indicate greater impairment of quality of life (QoL). An additional item, which does not contribute to the total impact score, asks the patient to rate the current severity of their condition on a 7-point scale ranging from 0 (no skin involvement) to 6 (most severe case).VitiQoL will be administered on a tablet during site visits according to the PRO assessment schedule, as described in the protocol study activity table.

[0109] The Dermatology Life Quality Index (DLQI) is a 10-item questionnaire developed and validated for use in measuring QoL in patients with skin diseases.3 It has been used in clinical practice and in several clinical trials to assess the impact of vitiligo symptoms and treatment on QoL.4 It consists of 10 questions that assess the impact of skin diseases on different aspects of an individual's QoL in the previous week. The DLQI measures several domains, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and treatment burden. Each item is scored on a 4-point scale: 0 = not at all / not relevant; 1 = somewhat; 2 = quite a lot; and 3 = very much. The item scores (0 to 3) are summed to provide a total score range of 0 to 30; higher scores indicate greater impairment of QoL.For general inflammatory skin conditions, a change in the DLQI score of at least 4 points is considered the minimum clinically important difference. Petition 870260018663, dated 27 / 02 / 2026, page 32 / 93 16 / 68

[0110] The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire, with 7 items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, and scores for the entire scale (emotional distress) range from 0 to 42, with higher scores indicating greater distress. For each domain, scores of 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression. The HADS will be administered on a tablet during site visits according to the PRO assessment schedule, as described in the protocol study activity table.

[0111] The Patient Global Impression of Change - Vitiligo (PaGIC-V) is a survey that asks individuals to rate the overall change in their vitiligo symptoms by comparing the severity of their vitiligo symptoms now with the severity of their vitiligo symptoms since they began the study treatment. Responses range from 1 = Much better to 5 = Much worse.

[0112] The Patient Global Assessment of Vitiligo - Total (T-PaGVA) and the Patient Global Assessment of Vitiligo - Face (F-PaGVA) are two region-specific patient global assessments that measure an individual's perceptions of their current vitiligo condition. Both are single-item questionnaires with 5-point categorical response options. The T-PaGVA measures an individual's perception of their vitiligo for all body regions. The F-PaGVA measures an individual's perception of their facial vitiligo. Each scale is constructed to ask about disease severity based on the extent of the area covered by depigmented skin. Response options range from 1 = no depigmentation to 5 = very extensive depigmentation.

[0113] The Vitiligo Extent Score (VES) is a clinical scoring tool to measure the overall involvement of vitiligo in the body (extent). The VES tool is based on clinical picture), involving 19 separate areas of the body, Petition 870260018663, dated 27 / 02 / 2026, p. 33 / 93 17 / 68 reflecting 6 degrees of involvement (Degree 0 to 6: involved by region 0%, 1%, 5%, 10%, 25%, 50% and 75%, respectively).

[0114] The Physician Global Assessment of Vitiligo - Total (T-PhGVA) and the Physician Global Assessment of Vitiligo - Face (F-PhGVA) are tools for quantifying the severity of vitiligo. They use a 5-point scale: 0 = no depigmentation; 1 = limited extent of depigmentation; 2 = moderate degree of depigmentation; 3 = extensive depigmentation; and 4 = very extensive depigmentation. T-PhGVA includes contributions from all body regions, while F-PhGVA includes contributions from the face.

[0115] The Physician Global Impression of Change regarding Vitiligo (PhGICV) is a survey in which the investigator rates the overall change in an individual's vitiligo symptoms by comparing the severity of vitiligo symptoms at the time of study with the severity of vitiligo symptoms since the individual began treatment. Responses range from 1 = Much better to 5 = Much worse.

[0116] The Individual Component Vitiligo Assessment (ICVA) is a paper-based questionnaire completed by the investigator and used to collect exploratory information about vitiligo involvement in the genitals and individual facial components using the following two assessments: PhGVA and the level of discomfort caused by the vitiligo lesions to the individuals. The level of discomfort is based on a question asked to the individual about how much their vitiligo in the genitals and individual facial areas bothers them and uses a 4-point scale: 1 = not bothersome at all; 2 = slightly bothersome; 3 = moderately bothersome; and 4 = extremely bothersome. There is also an N / A (not applicable) response option for areas not affected by vitiligo.The individual components of the face include the forehead / temples, around the eyes, nose, mid-cheek (medially to the outer corner of the eye), side cheek (laterally to the outer corner of the eye), around the mouth, lips, ears, and scalp. Petition 870260018663, dated 27 / 02 / 2026, p. 34 / 93 18 / 68 II. JAK1 Inhibition

[0117] Upadacitinib (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide), or a pharmaceutically acceptable salt or solid form thereof, is an oral Janus kinase (JAK) inhibitor that exhibits exclusive selectivity for the JAK1 receptor. Upadacitinib has the structure shown below:

[0118] The upadacitinib dosage intensity cited in this application is based on the weight of anhydrous freebase upadacitinib present in the active ingredient delivered to the patient. For example, a dose of 15 mg of upadacitinib or UPA 15 mg refers to the amount of 15 mg of neutral freebase upadacitinib present in the active ingredient, not including any coformers (e.g., solvent or water molecule(s)) of a solvate or hydrate (including hemihydrate) or counter-anions of a pharmaceutically acceptable salt), which may also be present in the active ingredient. Thus, for example, administration of 15 mg of upadacitinib includes the administration of 15.4 mg of crystalline freebase upadacitinib hemihydrate (which includes 1 / 2 of a water conformer molecule per molecule of freebase upadacitinib) that delivers 15 mg of anhydrous freebase upadacitinib to a patient. III. Treatment of Vitiligo

[0119] Treatment methods for vitiligo with the selective JAK1 inhibitor, upadacitinib, are provided here. Vitiligo is a common chronic autoimmune disorder. Petition 870260018663, dated 27 / 02 / 2026, page 35 / 93 Vitiligo is a disease that causes skin patches to lose pigmentation when melanocytes are attacked and destroyed, resulting in the skin taking on a milky white color. The global prevalence of vitiligo is approximately 0.5% to 2%. Early depigmentation usually occurs on the face and extremities. In 2011, an international consensus classified vitiligo into segmental vitiligo and non-segmental vitiligo (NSV; Ezzedine et al., Pigment Cell Melanoma Res. 2012, 25(3):E1-13). Most patients (>90%) exhibit the non-segmental variant, in which white patches usually appear symmetrically on both sides of the body, such as on both hands or both knees, with occasional rapid pigment loss, including over a large area. Hair (scalp, eyebrows, eyelashes, beard, and body) and mucous membranes may also lighten. NSV can occur at any age. Segmental vitiligo (SV), which differs in appearance and cause from NSV, is much less common.Segmental vitiligo (SV) tends to affect areas of skin associated with dorsal spinal cord roots and is most often unilateral, more stable / static in its progression, and does not improve with topical therapies or UV light. The segmental subtype of vitiligo usually begins at an early age, progressing for 6 to 12 months and then typically stopping.

[0120] Melanocyte impairment or death is believed to be the direct cause of vitiligo. Melanocytes produce the pigment melanin, which colors the skin and provides protection against UV radiation. Although several theories describe the pathogenesis of vitiligo, the exact etiology is unknown. The autoimmune theory hypothesizes that interferon (IFN)-γ is an important cytokine expressed in lesional skin and is necessary for the recruitment of melanocyte-specific autoreactive CD8+ T cells to the skin via the chemokines CXCL9 / 10 and CXCR3 (Rodrigues et al., J Am Acad Dermatol. 2017, 77(1):1-13; Harris et al., J Invest Dermatol. 2012, 132(7):1869-76). Cytotoxic CD8+ T cells are necessary and sufficient for the destruction of melanocytes in the skin of patients with vitiligo and therefore serve as Petition 870260018663, dated 27 / 02 / 2026, page 36 / 93 20 / 68 the effector arm that triggers the autoimmunity of vitiligo.

[0121] Overall, the effect of vitiligo on quality of life seems to be associated with the distribution of vitiligo lesions (e.g., face, genital area) and also with the extent of the disease, highlighting the unmet need for effective systemic therapies. There are few treatment options for vitiligo, and those that exist have limited efficacy. Thus, there is a lack of options for patients with vitiligo, particularly those with severe manifestations of the disease, given the limited response to currently available topical and systemic therapies. In view of the lack of treatment options and the emotional, psychological, and other costs associated with the disease, it is desirable in the art to provide patients with safe, well-tolerated, and effective therapies for the treatment of vitiligo. A. Adult Patient

[0122] Consequently, in one aspect, a method of treating vitiligo in an adult human patient is provided, wherein the method comprises administering orally once daily to the adult human patient 15 mg of upadacitinib.

[0123] In some modalities, the adult patient is in the age range of about 18 to about 65 years.

[0124] In some forms, the adult patient has non-segmental vitiligo (NSV).

[0125] In some modes, the NSV is stable.

[0126] In some modes, NSV is active.

[0127] In some modalities, the adult patient has, before starting treatment, a Facial Vitiligo Area Score Index F-VASI > 0.5.

[0128] In some modalities, the adult patient has, before starting treatment, a Total Vitiligo Area Score Index (T-VASI) > 5 T-VASI.

[0129] In some modalities, the adult patient did not receive any Petition 870260018663, dated 27 / 02 / 2026, page 37 / 93 21 / 68 immunomodulatory biological therapy before initiating treatment.

[0130] In some modalities, the adult patient did not receive any topical JAK inhibitor within 12 weeks of starting treatment.

[0131] In some modalities, the adult patient has leukotrichia in < 33% of the affected area.

[0132] In some modalities, the adult patient achieves F-VASI 75 in 24 weeks.

[0133] In some modalities, the adult patient obtains one or more of the following at 36 weeks: T-VASI 50, T-VASI 75, T-VASI 90, F-VASI 50, F-VASI 90.

[0134] In some modalities, the patient achieves T-VASI 50 in 48 weeks after the first daily administration.

[0135] In some modalities, the patient achieves F-VASI 75 in 48 weeks after the first daily administration.

[0136] In some modalities, the patient achieves T-VASI 50 in 52 weeks after the first daily administration.

[0137] In some modalities, the patient achieves F-VASI 75 in 52 weeks after the first daily administration.

[0138] In some modalities, the adult patient achieves an improvement in the Global Impression of Change for All on Vitiligo (PaGIC-V) at 36 weeks.

[0139] In some modalities, the adult patient obtains a score on the vitiligo perception scale (VNS) of very less noticeable (4) or no longer noticeable (5) at 36 weeks.

[0140] In some modalities, the adult patient achieves an improvement from baseline in the vitiligo extent score (VES) at 36 weeks.

[0141] In some modalities, the adult patient achieves an improvement from baseline in VitiQoL at 36 weeks.

[0142] In some modalities, the adult patient obtains a total score of Petition 870260018663, dated 27 / 02 / 2026, page 38 / 93 22 / 68 Dermatology Life Quality Index (DLQI) of 0 or 1 at 36 weeks.

[0143] In some modalities, the adult patient achieves an improvement from baseline in Hospital Anxiety and Depression Scale (HADS) scores at 36 weeks.

[0144] In some modalities, the adult patient achieves an improvement in the time to onset of repigmentation compared to a patient who was not treated with upadacitinib.

[0145] In some modalities, the adult patient obtains an improvement in itching or burning sensation within 36 weeks after the start of treatment.

[0146] In some modalities, the adult patient achieves a Physician Global Impression of Change score on Vitiligo (PhGIC-V) of much better (1) or somewhat better (2) at 36 weeks. In some modalities, the adult patient achieves a Patient Global Impression of Change score - Vitiligo (PaGIC-V) of much better (1) or somewhat better (2) at 36 weeks. In some modalities, the adult patient achieves a Physician Global Assessment of Vitiligo - Face (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks. In some modalities, the adult patient achieves a Physician Global Assessment of Vitiligo - Total (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks. In some modalities, the adult patient obtains a Patient-GVA-Vital Assessment of Vitiligo score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks.In some modalities, the adult patient obtains a Patient Global Assessment of Vitiligo - Total (T-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks.

[0147] In some modalities, the method halts the progression of vitiligo within 36 weeks of starting treatment. Petition 870260018663, dated 27 / 02 / 2026, page 39 / 93 23 / 68

[0148] In some modalities, the method results in a reduction from baseline in one or more vitiligo biomarkers within 36 weeks of treatment initiation. In some modalities, the biomarker is an inflammatory chemotactic protein or a T-cell activation marker. In some modalities, the biomarker is CXCL9, CXCL10, IL12B, TNFSF9, or a combination thereof.

[0149] In some modalities, the adult patient is concomitantly treated with exposure to ultraviolet light.

[0150] The disclosed methods generally involve administering upadacitinib orally to the adult patient daily for a period of time. In some embodiments, administration is continued at the same dose and dosing frequency over a treatment period. The duration of the treatment period may vary. For example, the treatment period may be at least one month, as well as 3 months, 4 months, 6 months, 9 months, 1 year, 2 years, 5 years, 10 years, 20 years, 50 years or more. In some embodiments, the treatment period is 24 weeks. In some embodiments, the treatment period is 36 weeks. In some embodiments, the treatment period is 52 weeks. In some embodiments, the treatment period is at least 24 weeks or at least 36 weeks. In some embodiments, the treatment period is 48 weeks. B. Pediatric Patient

[0151] In some embodiments, the vitiligo patient is a pediatric human patient (i.e., less than about 18 years of age). In some embodiments, the dose administered to a pediatric patient may differ from that of an adult human patient.

[0152] Consequently, in another aspect, a method of treating vitiligo in a pediatric human patient is provided. The method generally comprises administering upadacitinib to the pediatric patient as a formulation Petition 870260018663, dated 27 / 02 / 2026, page 40 / 93 24 / 68 stable oral pharmaceutical dosage form or a prolonged-release tablet, with dosing based on body weight. The amount of upadacitinib administered, the oral dosage form, and the dosing frequency (e.g., once or twice daily) will vary based on the patient's weight.

[0153] In some modalities, the pediatric patient is younger than 18 years. In some modalities, the pediatric patient is younger than 12 years. In some modalities, the pediatric patient is younger than 6 years. In some modalities, the pediatric patient is between about 2 and less than about 6 years old, between about 6 and less than about 12 years old, or between about 12 and less than about 18 years old. In some modalities, the pediatric patient is aged between approximately 2 and approximately 18 years, such as approximately 2, approximately 3, approximately 4, approximately 5, approximately 6, approximately 7, approximately 8, approximately 9, approximately 10, approximately 11, approximately 12, approximately 13, approximately 14, approximately 15, approximately 16, approximately 17, or approximately 18 years of age.

[0154] In some modalities, the pediatric patient has a body weight of at least about 10 kg. In some modalities, the pediatric patient has a body weight of about 10 kg to less than about 30 kg, such as from about 20 to less than about 20 kg, or from about 20 to less than about 30 kg. In some modalities, the pediatric patient has a body weight of 30 kg or more.

[0155] In some modalities, the pediatric patient has a body weight in a range of about 10 to less than about 20 kg, the method comprising administering 3 mg of upadacitinib twice daily (3 mg BID) as an oral solution.

[0156] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.9 mg / ml to about 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a Petition 870260018663, dated 27 / 02 / 2026, p. 41 / 93 25 / 68 concentration of 1.0 mg / ml.

[0157] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 1 mg / ml, and the 3 mg dose is given BID, as approximately 3 ml of the approximately 1 mg / ml solution.

[0158] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.5 mg / ml, such as about 0.3, 0.4 or about 0.5 to about 0.6, or about 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.4 mg / ml to about 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 0.5 mg / ml.

[0159] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, and the 3 mg dose is given BID, as approximately 6 ml of the approximately 0.5 mg / ml solution.

[0160] In some modalities, the pediatric patient has a body weight in a range of about 10 to less than about 20 kg, the method comprising administering 6 mg of upadacitinib twice daily (6 mg BID) as an oral solution.

[0161] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.9 mg / ml to about 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 1.0 mg / ml.

[0162] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 1 mg / ml, and the 6 mg dose is given BID, as approximately 6 ml of the approximately 1 mg / ml solution.

[0163] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, as well as approximately 0.3, 0.4 or approximately Petition 870260018663, dated 27 / 02 / 2026, p. 42 / 93 26 / 68 0.5 to approximately 0.6, or approximately 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.4 mg / ml to approximately 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 0.5 mg / ml.

[0164] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, and the 6 mg dose is given BID, as approximately 12 ml of the approximately 0.5 mg / ml solution.

[0165] In some embodiments, the pediatric patient has a body weight in the range of about 20 to less than about 30 kg, the method comprising administering 4 mg of upadacitinib twice daily (4 mg BID) as an oral solution. In some embodiments, the pediatric patient has a body weight in the range of about 20 to less than about 30 kg, the method comprising administering 8 mg of upadacitinib twice daily (8 mg BID) as an oral solution.

[0166] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.9 mg / ml to about 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 1.0 mg / ml.

[0167] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 1 mg / ml, and the 8 mg dose is given BID, as approximately 8 ml of the approximately 1 mg / ml solution.

[0168] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.5 mg / ml, such as about 0.3, 0.4 or about 0.5 to about 0.6, or about 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.4 mg / ml to about 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib to Petition 870260018663, dated 27 / 02 / 2026, p. 43 / 93 27 / 68 a concentration of 0.5 mg / ml.

[0169] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, and the 8 mg dose is given BID, as approximately 16 ml of the approximately 0.5 mg / ml solution.

[0170] In some modalities, the pediatric patient has a body weight of approximately 30 kg or more, the method comprising the administration of 6 mg of upadacitinib twice daily (6 mg BID) as an oral solution.

[0171] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.9 mg / ml to about 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 1.0 mg / ml.

[0172] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 1 mg / ml, and the 6 mg dose is given BID, as approximately 6 ml of the approximately 1 mg / ml solution.

[0173] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.5 mg / ml, such as about 0.3, 0.4 or about 0.5 to about 0.6, or about 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.4 mg / ml to about 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 0.5 mg / ml.

[0174] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, and the 6 mg dose is given BID, as approximately 12 ml of the approximately 0.5 mg / ml solution.

[0175] In some modalities, the pediatric patient has a body weight of approximately 30 kg or more, and the method involves administering 15 mg of Petition 870260018663, dated 27 / 02 / 2026, p. 44 / 93 28 / 68 upadacitinib once daily (15 mg QD) as an extended-release tablet.

[0176] In some embodiments, the pediatric patient has a body weight of about 30 kg or more, the method comprising administering 8 mg of upadacitinib twice daily (8 mg BID) as an oral solution.

[0177] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.9 mg / ml to about 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 1.0 mg / ml.

[0178] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 1 mg / ml, and the 8 mg dose is given BID, as approximately 8 ml of the approximately 1 mg / ml solution.

[0179] In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.5 mg / ml, such as about 0.3, 0.4 or about 0.5 to about 0.6, or about 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 0.4 mg / ml to about 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 0.5 mg / ml.

[0180] In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, and the 8 mg dose is given BID, as approximately 16 ml of the approximately 0.5 mg / ml solution.

[0181] In some modalities, the pediatric patient has a body weight of approximately 30 kg or more, and the method involves administering 15 mg of upadacitinib once daily (15 mg QD) as an extended-release tablet.

[0182] The maximum concentration obtained (Cmax) with the dosage mentioned above may vary depending on, for example, the dose, patient weight and Petition 870260018663, dated 27 / 02 / 2026, p. 45 / 93 29 / 68 of the individual patient's metabolism of upadacitinib.

[0183] In some embodiments, when an immediate-release oral solution, as described in this document, is administered twice daily to the pediatric individual, a mean Cmax for upadacitinib is achieved in a range of about 20 to about 160 ng / ml.

[0184] In some embodiments, when administered twice daily at a dose of 3 or 4 mg each (3 or 4 mg 2x / day) to the pediatric individual, a mean Cmax for upadacitinib is obtained in a range of about 25 to about 50 ng / ml, such as about 25 to about 35, about 25 to about 33, about 25 to about 31, about 25 to about 29 or about 25 to about 27 ng / ml.

[0185] In some embodiments, when administered twice daily at a dose of 6 or 8 mg each (6 or 8 mg 2x / day) to the pediatric individual, a mean Cmax for upadacitinib is achieved in a range of about 40 to about 100 ng / ml, such as about 40 to about 95, about 40 to about 90, about 40 to about 85, about 40 to about 80, about 40 to about 75, about 40 to about 70, about 40 to about 65, about 40 to about 60, about 40 to about 55, about 40 to about 50, or about 40 to about 45 ng / ml.

[0186] In some embodiments, when a 15 mg extended-release tablet, as described herein, is administered once daily (15 mg 1x / day) to the pediatric individual, a mean Cmax for upadacitinib is achieved in a range of about 45 to about 50 ng / ml, such as about 45 to about 49, about 45 to about 48, about 45 to about 46, or about 45 to about 46 ng / ml.

[0187] The mean 24-hour exposure achieved (AUC0-24) with the above-mentioned dosage may vary depending, for example, on the dose, the patient's weight, whether they were fed or fasted, and upadacitinib metabolism. Petition 870260018663, dated 27 / 02 / 2026, page 46 / 93 30 / 68 individual patient.

[0188] In some embodiments, when an immediate-release oral solution, as described herein, is administered twice daily to the pediatric individual, a mean AUC0-24 for upadacitinib is achieved in a range of about 200 to about 700 ng^h / ml.

[0189] In some embodiments, when administered twice daily at a dose of 3 or 4 mg each (3 or 4 mg 2x / day) to the pediatric individual, a mean AUC0-24 for upadacitinib is achieved in a range of approximately, such as from approximately 220 to approximately 270 ng^h / ml, from approximately 220 to approximately 265, from approximately 220 to approximately 260, from approximately 220 to approximately 255, from approximately 220 to approximately 250, from approximately 220 to approximately 245, from approximately 220 to approximately 240, from approximately 220 to approximately 235, from approximately 220 to approximately 230, or from approximately 220 to approximately 225 ng^h / ml.

[0190] In some embodiments, when administered twice daily at a dose of 6 or 8 mg each (6 or 8 mg 2x / day) to the pediatric individual, a mean AUC0-24 for upadacitinib is obtained in a range of about 340 to about 590 ng^h / ml, such as about 340 to about 580, about 340 to about 570, about 340 to about 560, about 340 to about 550, about 340 to about 540, about 340 to about 530, about 340 to about 520, about 340 to about 510, about 340 to about 500, about 340 to about 490, about 340 to about from about 480, from about 340 to about 470, from about 340 to about 460, from about 340 to about 450, from about 340 to about 440, from about 340 to about 430, from about 340 to about 420, from about 340 to about 410, from about 340 to about 400, from about 340 to about 390, from about 340 to about 380, from about 340 to about 370, from about 340 to about 360,from approximately 340 to approximately 350 or from approximately 340 to approximately 345 ng^h / ml. In some embodiments, when administered twice daily at a dose of 6 or 8 mg each (6 or 8 mg 2x / day) to the pediatric individual, a mean AUC0-24 for upadacitinib is, Petition 870260018663, dated 27 / 02 / 2026, p. 47 / 93 31 / 68 achieved in a range of about 570 to about 590 ng^h / ml, such as from about 570 to about 590, from about 570 to about 588, from about 570 to about 586, from about 570 to about 584, from about 570 to about 582 or from about 570 to about 580 ng^h / ml.

[0191] In some embodiments, when a 15 mg extended-release tablet, as described herein, is administered once daily (15 mg 1x / day) to the pediatric individual, a mean AUC0-24 for upadacitinib is achieved in a range of about 45 to about 50 ng^h / ml, such as about 45 to about 49, about 46 to about 48, or about 47 to about 48 ng^h / ml.

[0192] In some forms, the pediatric patient has non-segmental vitiligo (NSV).

[0193] In some modes, the NSV is stable.

[0194] In some modes, NSV is active.

[0195] In some modalities, the pediatric patient has, before starting treatment, a Facial Vitiligo Area Score Index (F-VASI) > 0.5.

[0196] In some modalities, the pediatric patient has, before starting treatment, a Total Vitiligo Area Score Index (T-VASI) > 5.

[0197] In some modalities, the pediatric patient has not received any immunomodulatory biological therapy prior to starting treatment.

[0198] In some modalities, the pediatric patient did not receive any topical JAK inhibitor within 12 weeks of starting treatment.

[0199] In some modalities, the pediatric patient has leukotrichia in < 33% of the affected areas.

[0200] In some modalities, the pediatric patient achieves F-VASI 75 within 24 weeks of starting treatment.

[0201] In some modalities, the pediatric patient receives one or more of a T-VASI 50, a T-VASI, or a T-VASI within 36 weeks of starting treatment. Petition 870260018663, dated 27 / 02 / 2026, page 48 / 93 32 / 68 75, a T-VASI 90, an F-VASI 50 or an F-VASI 90.

[0202] In some modalities, the pediatric patient achieves F-VASI 75 at 36 weeks after the start of treatment.

[0203] In some modalities, the pediatric patient achieves T-VASI 50 at 36 weeks after the start of treatment.

[0204] In some modalities, the pediatric patient receives one or more of a T-VASI 50, a T-VASI 75, a T-VASI 90, an F-VASI 50, or an F-VASI 90 within 48 weeks of starting treatment.

[0205] In some modalities, the pediatric patient achieves F-VASI 75 48 weeks after starting treatment.

[0206] In some modalities, the pediatric patient achieves T-VASI 50 within 48 weeks after starting treatment.

[0207] In some modalities, the pediatric patient obtains one or more of a T-VASI 50, a T-VASI 75, a T-VASI 90, an F-VASI 50, or an F-VASI 90 within 52 weeks of starting treatment.

[0208] In some modalities, the pediatric patient achieves F-VASI 75 at 52 weeks after the start of treatment.

[0209] In some modalities, the pediatric patient achieves T-VASI 50 at 52 weeks after the start of treatment.

[0210] In some modalities, the pediatric patient achieves an improvement in the Patient's Global Impression of Change regarding Vitiligo (PaGIC-V) 36 weeks after the start of treatment.

[0211] In some modalities, the pediatric patient obtains a score on the vitiligo perception scale (VNS) of much less noticeable (4) or no longer noticeable (5) 36 weeks after the start of treatment.

[0212] In some modalities, the pediatric patient achieves an improvement from baseline in the vitiligo extent score (VES) at 36 weeks. Petition 870260018663, dated 27 / 02 / 2026, page 49 / 93 33 / 68 after the start of treatment.

[0213] In some modalities, the pediatric patient achieves an improvement from baseline in VitiQoL 36 weeks after the start of treatment.

[0214] In some modalities, the pediatric patient obtains a total score of 0 or 1 on the Dermatology Life Quality Index (DLQI) at 36 weeks.

[0215] In some modalities, the pediatric patient achieves an improvement from baseline in Hospital Anxiety and Depression Scale (HADS) scores 36 weeks after the start of treatment.

[0216] In some modalities, the pediatric patient achieves an improvement in the time to onset of repigmentation compared to a patient who was not treated with upadacitinib.

[0217] In some modalities, the pediatric patient obtains an improvement in itching or burning sensation within 36 weeks after the start of treatment.

[0218] In some modalities, the pediatric patient achieves a Physician Global Impression of Change in Vitiligo (PhGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after treatment initiation. In some modalities, the pediatric patient achieves a Patient Global Impression of Change in Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after treatment initiation. In some modalities, the pediatric patient achieves a Physician Global Assessment of Vitiligo - Face (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after treatment initiation. In some modalities, the pediatric patient obtains a Physician Global Assessment of Vitiligo - Total (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the start of treatment.In some modalities, the pediatric patient obtains a Patient-GVA Global Assessment of Vitiligo score of no depigmentation (0) or limited extent. Petition 870260018663, dated 27 / 02 / 2026, page 50 / 93 34 / 68 depigmentation (1) at 36 weeks after the start of treatment. In some modalities, the pediatric patient obtains a Patient Global Assessment of Vitiligo - Total (T-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the start of treatment.

[0219] In some modalities, the method halts the progression of vitiligo within 36 weeks of starting treatment.

[0220] In some modalities, the method results in a reduction from baseline in one or more vitiligo biomarkers within 36 weeks of treatment initiation. In some modalities, the biomarker is an inflammatory chemotactic protein or a T-cell activation marker. In some modalities, the biomarker is CXCL9, CXCL10, IL12B, TNFSF9, or a combination thereof.

[0221] In some modalities, the pediatric patient is concomitantly treated with exposure to ultraviolet light.

[0222] The disclosed method generally involves administering upadacitinib orally to the pediatric patient daily for a period of time. In some embodiments, administration is continued at the same dose and dosing frequency over a treatment period. The duration of the treatment period may vary. For example, the treatment period may be at least one month, such as 3 months, 4 months, 6 months, 9 months, 1 year, 2 years, 5 years, 10 years, 20 years, 50 years or more. In some embodiments, the treatment period is 24 weeks. In some embodiments, the treatment period is at least 24 weeks or at least 36 weeks. In some embodiments, the treatment period is 36 weeks. In some embodiments, the treatment period is 48 weeks. In some embodiments, the treatment period is 52 weeks. III. Pharmaceutical compositions and routes of administration

[0223] Upadacitinib can be administered to a human patient Petition 870260018663, dated 27 / 02 / 2026, page 51 / 93 35 / 68 alone or in a pharmaceutical composition where biologically suitable carrier(s) or excipient(s) are mixed in doses to treat or alleviate a disease or condition, as described herein. Mixtures of these compounds may also be administered to the patient as a simple mixture or in appropriately formulated pharmaceutical compositions.

[0224] The pharmaceutical compositions of the present disclosure can be manufactured by a method that is itself known, for example, by means of conventional processes of mixing, dissolving, granulating, producing dragees, levigating, emulsifying, encapsulating, trapping or lyophilizing.

[0225] Pharmaceutical compositions for use according to the present disclosure can thus be formulated using a conventional method with the use of one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate the processing of the active compounds into preparations that can be used pharmaceutically. The appropriate formulation depends on the chosen route of administration.

[0226] In some embodiments, the pharmaceutical composition is a tablet dosage form. In some embodiments, the tablet is a controlled-release formulation, such as a prolonged-release tablet dosage form (also referred to herein as a modified-release or prolonged-release formulation). Examples of solid dosage forms comprising upadacitinib can be found in international patent application publication WO2017 / 066775, which is incorporated herein by reference in its entirety.

[0227] In some embodiments, the composition is a stable liquid pharmaceutical composition. In some embodiments, the stable liquid pharmaceutical composition is a stable oral solution. In some embodiments, the stable liquid pharmaceutical composition is a stable oral suspension. Suitable stable liquid pharmaceutical compositions comprise upadacitinib or a salt. Petition 870260018663, dated 27 / 02 / 2026, page 52 / 93 36 / 68 pharmaceutically acceptable or solid form thereof, together with excipients such as buffers, preservatives, sweeteners, flavoring agents, pH adjusters, solvents and the like. In some embodiments, the stable liquid pharmaceutical composition is a stable oral pharmaceutical solution comprising upadacitinib, a buffer and / or pH adjuster, a preservative, a sweetener and water. In some embodiments, the stable liquid pharmaceutical composition is a stable oral pharmaceutical suspension comprising upadacitinib, a buffer and / or pH adjuster, a preservative, a sweetener and water.

[0228] The concentration of upadacitinib in the stable liquid pharmaceutical composition may vary. Due to the bitterness of upadacitinib, which is difficult to mask at higher concentrations for palatability (see, for example, Example 5), it is generally present at about 1 mg / ml or less. In some embodiments, the stable pharmaceutical composition is an oral solution comprising: upadacitinib at a concentration in a range of about 0.3 mg / ml to about 1.2 mg / ml, such as from about 0.3 to about 0.7 mg / ml, or from about 0.8 to about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of about 1 mg / ml, such as from about 0.8, 0.9 or about 1.0 to about 1.1, or about 1.2 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.9 mg / ml to approximately 1.1 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 1.0 mg / ml.In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.5 mg / ml, such as approximately 0.3, 0.4, or approximately 0.5 to approximately 0.6, or approximately 0.7 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of approximately 0.4 mg / ml to approximately 0.6 mg / ml. In some embodiments, the oral solution comprises upadacitinib at a concentration of 0.5 mg / ml. Petition 870260018663, dated 27 / 02 / 2026, p. 53 / 93 37 / 68

[0229] In some embodiments, the oral solution additionally comprises a pH adjusting agent. Suitable pH adjusting agents include acids, such as mineral or organic acids. Mineral acids include, but are not limited to, hydrochloric, sulfuric, and phosphoric acids. As used herein, the term organic acid refers to an organic (i.e., carbon-based) compound that is characterized by acidic properties. Typically, organic acids are relatively weak acids (i.e., they do not dissociate completely in the presence of water), such as carboxylic acids (-CO2H). In some embodiments, the pH adjusting agent is an organic acid. Suitable organic acids include, but are not limited to, benzoic acid, toluic acids, salicylic acid, benzenesulfonic acid, ptoluenesulfonic acid, 2-(4-isobutylphenyl)propanoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid,adipic acid, ascorbic acid (L), aspartic acid (L), alpha-methylbutyric acid, camphoric acid (+), camphor-10-sulfonic acid (+), cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, fumaric acid, furoic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, isovaleric acid, lactobionic acid, lauric acid, levulinic acid, malic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oleic acid, palmitic acid, acid Pamoic acid, phenylacetic acid, pyroglutamic acid, pyruvic acid, sebacic acid, stearic acid, tartaric acid, and undecylenic acid. In some embodiments, the pH adjusting agent is selected from the group consisting of citric acid,Phosphoric acid, tartaric acid, succinic acid, formic acid, acetic acid, and combinations thereof. In some embodiments, the pH adjusting agent is citric acid.

[0230] In some embodiments, the stable liquid pharmaceutical composition Petition 870260018663, dated 27 / 02 / 2026, page 54 / 93 38 / 68 comprises a buffer. Suitable buffers include, but are not limited to, citrate, phosphate, tartrate, succinate, glycinate, glycerophosphate, formate, and acetate. In some embodiments, the buffer is selected from the group consisting of citrate, phosphate, tartrate, succinate, formate, acetate, and combinations thereof. In some embodiments, the buffer is selected from the group consisting of citrate and phosphate. In some embodiments, the buffer is sodium citrate.

[0231] The amount of pH adjusting agent and / or buffer may vary. Generally, the concentration of each is adjusted to provide a desired pH range for the resulting stable liquid pharmaceutical composition.In some embodiments, the stable liquid pharmaceutical composition has a pH in the range of about 2 to about 5, or about 3 to about 4, or about 2 to about 3, or about 4 to about 5, or about 2.0 to about 2.5, or about 2.5 to about 3.0, or about 3.0 to about 3.5, or about 3.5 to about 4.0, or about 4.0 to about 4.5, or about 4.5 to about 5.0, or about 3.0 to about 3.1, or about 3.0 to about 3.2, or about 3.0 to about 3.3, or about 3.1 to about 3.2, or about 3.1 to about 3.3, or about 3.1 to about 3.4, or from about 3.1 to about 3.5, or from about 3.2 to about 3.3, or from about 3.2 to about 3.4, or from about 3.2 to about 3.5, or from about 3.3 to about 3.4, or from about 3.3 to about 3.5. In some embodiments, the stable liquid pharmaceutical composition has a pH of about 3.0, or about 3.1, or about 3.2.

[0232] In some embodiments, the stable liquid pharmaceutical composition comprises a preservative. Suitable preservatives include, but are not limited to, benzoic acid, sodium benzoate, benzyl alcohol, ascorbic acid, potassium sorbate, 4-hydroxybenzoic acid, 4-hydroxybenzoate, methylparaben, propylparaben, sodium metabisulfite, and combinations thereof. In some embodiments, the preservative is selected from the group consisting of sodium benzoate, benzoic acid, Petition 870260018663, dated 27 / 02 / 2026, page 55 / 93 39 / 68 propyl paraben, sodium metabisulfite, potassium sorbate, hydroxyparabenzoic acid, hydroxyparabenzoate and combinations thereof.

[0233] In some embodiments, the stable liquid pharmaceutical composition comprises a sweetener. The sweetener may be any sweetener or combination of sweeteners, in natural or artificial form, or as a combination of natural and artificial sweeteners. Examples of natural sweeteners include fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, honey, and the like. Examples of artificial sweeteners include sucralose, isomaltulose, maltodextrin, saccharin, aspartame, acesulfame K, neotame, and the like. In some embodiments, the sweetener comprises one or more sugar alcohols. Sugar alcohols are polyols derived from monosaccharides or disaccharides that have a partially or fully hydrogenated form.Sugar alcohols, for example, have from about 4 to about 20 carbon atoms, and include erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof (e.g., hydrogenated starch hydrolysates). In some embodiments, the sweetener is selected from the group consisting of sucralose, acesulfame potassium, sodium saccharin, neotame, sucrose, maltitol, xylitol, and combinations thereof.

[0234] In some embodiments, the stable oral pharmaceutical solution comprises one or more flavoring agents. Any flavoring or aromatic substance capable of altering the taste, fragrance, or both of the solution may be used. Flavoring agents may be natural or synthetic. Suitable flavoring agents include, but are not limited to, flavor packets that impart flavors such as cherry, orange, lemon, lime, bubblegum, grape, strawberry, mango, and the like.

[0235] In some embodiments, the stable oral pharmaceutical solution comprises a taste modifier. Suitable taste modifiers include, but are not limited to, salts such as sodium chloride and monoammonium glycyrrhizinate, for Petition 870260018663, dated 27 / 02 / 2026, page 56 / 93 40 / 68 accentuate the sweetness.

[0236] In some embodiments, the stable pharmaceutical composition is an oral solution comprising upadacitinib, citric acid, sodium citrate, sodium benzoate, sweetener and water.

[0237] In some embodiments, the stable pharmaceutical composition comprises citric acid in an amount in the range of about 0.1 to about 1 mg / ml.

[0238] In some embodiments, the stable pharmaceutical composition comprises sodium citrate in an amount in the range of about 0.01 to about 1 mg / ml.

[0239] In some embodiments, the stable pharmaceutical composition comprises sodium benzoate in an amount in the range of about 0.01 to about 0.1 mg / ml.

[0240] In some embodiments, the stable pharmaceutical composition comprises a sweetener in an amount in the range of about 1 to about 50 mg / ml.

[0241] In specific modalities, the oral solution has a formulation as provided in Table 1. Table 1. Example of an oral solution formulation for upadacitinib. Component mg / ml upadacitinib 0.3 to 1.2 citric acid, anhydrous 0.15 to 0.35 sodium citrate dihydrate 0.03 to 0.06 sodium benzoate 0.02 to 0.06 sucralose 7 to 11 purified water qs to 1 ml Exemplification Example 1: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of upadacitinib in individuals with non-segmental vitiligo. Petition 870260018663, dated 27 / 02 / 2026, page 57 / 93 41 / 68

[0242] This study was a 52-week, double-blind, Phase 2, multiple-dose, placebo-controlled clinical trial in adult patients with non-segmental vitiligo. The study had two periods. The first period was a 24-week study and was followed by a 28-week blinded extension period that was blinded but not placebo-controlled. A study layout is shown in Figure 1.

[0243] The primary objective of this study was to evaluate the safety and efficacy of upadacitinib for the treatment of adult individuals with non-segmental vitiligo (NSV). The primary endpoint was the percent change from baseline in the Facial Vitiligo Area Score Index (F-VASI) at Week 24. Inclusion / exclusion criteria

[0244] Eligible individuals were adult women and men > 18 to 65 years of age, inclusive, at screening with a documented clinical diagnosis of NSV and without segmental or localized vitiligo. Individuals had stable or active NSV. Approximately 130 adult male or female individuals were enrolled. Enrolled individuals met all of the following criteria at screening and baseline: • Facial Vitiligo Area Score Index (F-VASI) > 0.5 and Total Vitiligo Area Score Index (T-VASI) > 5. • Individuals with other skin conditions that would interfere with the vitiligo assessment, individuals with uncontrolled thyroid disease, and individuals with > 33% leukotrichia on the face or > 33% leukotrichia on the body (including the face) were not eligible to enroll in this study. • Eligible individuals must not have been previously treated with any topical or systemic JAK inhibitors or permanent skin-lightening agents. • Individuals must not have been treated with any systemic vitiligo therapy (e.g., methotrexate, mycophenolate mofetil, corticosteroids), therapy Petition 870260018663, dated 27 / 02 / 2026, page 58 / 93 42 / 68 supplemental vitiligo treatment (antioxidants / vitamins / herbal medicine / traditional Chinese medicine) and / or topical vitiligo therapy, including permanent or temporary tattoos, at least 30 days before the first dose of the study medication (Note: camouflage and makeup may be used). • Eligible individuals must not have been treated with any phototherapy, including excimer (or other forms of laser therapy), for a minimum of 12 weeks prior to the first dose of the study medication. • Individuals who have had prior exposure to immunomodulatory biological therapy, for any indication, must have discontinued the biological therapy before the first dose of the study drug. Recommended elimination periods for biological therapies include > 4 weeks for etanercept; > 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; > 16 weeks for secukinumab; and > 12 weeks for ustekinumab. For unspecified biological therapies, therapies must have been discontinued at least 5 times the mean terminal elimination half-life of a drug or 3 months before baseline, whichever is longer. • Laboratory values ​​that meet the following criteria within the screening period prior to the first dose of the study drug needed to be: • Serum aspartate transaminase (AST) ≤ 2 ≤ upper limit of normal (ULN) • Serum alanine transaminase (ALT) ≤ 2 ≤ ULN • Estimated glomerular filtration rate > 30 ml / min / 1.73 m2 using the simplified 4-variable modification of diet in renal disease (MDRD) formula • Total WBC count > 2500 / μl • Absolute neutrophil count (ANC) > 1200 / μl Petition 870260018663, dated 27 / 02 / 2026, page 59 / 93 43 / 68 • Platelet count > 100,000 / μl • Absolute lymphocyte count (ALC) > 750 / μl • Hemoglobin > 9 g / dl • Patients may not have had a current or past history of the following: • Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster • One or more episodes of disseminated herpes simplex (including herpetic eczema / Kaposi's varicelliform eruption) • Human immunodeficiency virus (HIV) infectionDefined as a confirmed positive test for anti-HIV antibody (HIV Ab) • Active tuberculosis (TB) or meeting TB exclusion criteria • Positive beta-D-glucan test (screening for Pneumocystis jirovecii infection) or 2 consecutive indeterminate beta-D-glucan results during the screening period (for individuals in Japan only) • Active infection(s) requiring treatment with intravenous anti-infectives within 30 days or oral / intramuscular (IM) anti-infectives within 14 days prior to the baseline visit • Chronic relapsing infection and / or active viral infection • Confirmed COVID-19 • Hepatitis B virus (HBV): positive (+) test for hepatitis B surface antigen or detectable qualitative PCR test for HBV DNA for individuals who are positive (+) for hepatitis B core antibody (HBc Ab) (and for hepatitis B surface antibodies) hepatitis B [HBs Ab] positive [+],(when required by local regulations) • Hepatitis C virus (HCV): HCV RNA detectable in any individual with anti-HCV antibodies. • Recent stroke (within the last 6 months), myocardial infarction, Petition 870260018663, dated 27 / 02 / 2026, p. 60 / 93 44 / 68 Coronary stent implantation and coronary artery bypass graft surgery • History of organ transplantation requiring ongoing immunosuppression • History of gastrointestinal perforation (except due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk of gastrointestinal perforation according to the investigator's judgment • Conditions that may interfere with drug absorption, including but not limited to short bowel syndrome or gastric bypass surgery; individuals with a history of gastric problems • Banding / segmentation is not excluded • History of malignancy,Except for successfully treated NMSC or localized carcinoma in situ of the cervix • Uncontrolled thyroid disease • Other skin conditions that would interfere with the assessment of vitiligo • > 33% leukotrichia on the face or > 33% leukotrichia on the body (including the face) • Systemic use of known strong CYP3A inhibitors (including over-the-counter or prescription medications, vitamins and / or herbal supplements) was not permitted from screening until the end of study drug administration, and the use of strong CYP3A inducers was not permitted from 30 days before study drug administration until the end of study drug administration. Furthermore, herbal therapies or other traditional medicines with unknown effects on CYP3A were not permitted from screening until the end of study drug administration. Study drug and treatment duration [ 0245] The study consisted of a 35-day screening period, a 24-week double-blind treatment period (Period 1), a 28-week long-term blinded extension (Period 2), and a 30-day follow-up period. Petition 870260018663, dated 27 / 02 / 2026, pp. 61 / 93 45 / 68 days. Individuals who met the eligibility criteria at baseline were randomized in a 2:2:2:1:1 ratio to one of five treatment groups as follows: • Group 1: upadacitinib 22 mg once daily (QD) (N = 40) (Period 1) ^ upadacitinib 22 mg QD (Period 2) • Group 2: upadacitinib 11 mg QD (N = 40) (Period 1) ^ upadacitinib 11 mg QD (Period 2) • Group 3: upadacitinib 6 mg QD (N = 40) (Period 1) ^ upadacitinib 6 mg QD (Period 2) • Group 4: placebo (N = 20) (Period 1) ^ upadacitinib 22 mg bQD (Period 2) • Group 5: placebo (N = 20) (Period 1) ^ upadacitinib 11 mg QD (Period 2)

[0246] Upadacitinib was administered orally once daily (QD). Stratification

[0247] Patients were randomized and stratified according to: • Age (50 or younger; older than 50) • Disease severity at baseline (T-VASI less than 15 or greater than or equal to 15) • Active vitiligo study (Yes / No) Study objectives and outcomes Final points of the effectiveness test. [ 0248] The following effectiveness parameters were used. Primary test endpoint: • Percentage change from baseline in F-VASI at Week 24 with upadacitinib treatment compared with placebo in the Intention-to-Treat (ITT) population, consisting of all randomized individuals. Final points for the secondary school test: Petition 870260018663, dated 27 / 02 / 2026, pp. 62 / 93 46 / 68 • Proportion of individuals who achieved F-VASI 75, defined as at least a 75% improvement in F-VASI from baseline at Week 24 • Proportion of individuals who achieved F-VASI 50, defined as at least a 50% improvement in F-VASI from baseline at Week 24 • Proportion of individuals who achieved T-VASI 50, defined as at least a 50% improvement in T-VASI from baseline at Week 24 • Percentage change (%) from baseline in T-VASI at Week 24 • Change from baseline in the total score of the Vitiligo Quality of Life Instrument (VitiQoL) at Week 24 Additional test endpoints • Achievement of F-VASI 90 • Achievement of T-VASI 90 • Achievement of T-VASI 75 • Mean and percentage change from baseline in the vitiligo extent score (VES) • Achievement of a vitiligo perception scale (VNS) score of much less noticeable (4) or no longer noticeable (5) • Total score of the Dermatology Life Quality Index (DLQI) of 0 or 1 • Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores • Proportion of individuals selecting each of the response categories for the VitiQoL 16 questions • Physician Global Impression of Change (PhGIC-V) score of much better (1) or somewhat better (2) • Patient Global Impression of Change - Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) Petition 870260018663, dated 27 / 02 / 2026, pp. 63 / 93 47 / 68 • Obtaining a Global Assessment of Vitiligo by the Physician - face (F-PhGVA) of no depigmentation (0) or limited extent of depigmentation (1) • Obtaining a Global Assessment of Vitiligo by the Physician - Total (T-PhGVA) of no depigmentation (0) or limited extent of depigmentation (1) • Obtaining a Global Assessment of Vitiligo by the Patient - Face (F-PaGVA) of no depigmentation (0) or limited extent of depigmentation (1) • Obtaining a Global Assessment of Vitiligo by the Patient - Total (T-PaGVA) of no depigmentation (0) or limited extent of depigmentation (1) Results Demographic data [ 0249] The study enrolled a high percentage of individuals with extensive vitiligo (T-VASI > 10 BSA) and / or active vitiligo. Baseline demographics of the overall study population and of each group (placebo, 6 mg, 11 mg, 22 mg dose) are provided in Table 2. Baseline disease characteristics (e.g., active vs. stable, years since diagnosis, disease severity, etc.) are provided in Table 3. Table 2. Patient demographic data PBO n=46 Upadacitinib 6 mg QD N=49 Upadacitinib 11 mg QD N=47 Upadacitinib 22 mg QD N=43 TOTAL N=185 Female, n (%) 29 (63) 26 (53.1) 34 (72.3) 26 (60.5) 115 (62.2) Age (years), mean (SD) 46.8 (10.5) 45.1 (11.7) 45.5 (11.9) 48.2 (11.1) 46.3 (11.3) Age group < 50 years, n (%) 26 (56.5) 28 (57.1) 28 (59.6) 25 (58.1) 107 (57.8) Race, n (%) • White • Black / African American • Asian 32 (76.2) 4 (9.5) 6 (14.3) 32 (71.1) 3 (6.7) 6 (13.3) 33 (75.0) 3 (6.8) 7 (15.9) 33 (78.6) 1 (2.4) 6 (14.3) 130 (75.1) 11 (6.4) 25 (14.5) Hispanic, n (%) 5 (10.9) 6 (12.2) 4 (8.5) 5 (11.6) 20 (10.8) BMI (kg / m2), average (SD) 27.3 (8.1) 27.6 (5.7) 27.5 (6.6) 27.9 (5.8) 27.6 (6.6) Skin types of 3 (6.5) 1 (2) 1 (2,1) 1 (2,3) 6 (3,2) Petition 870260018663, dated 27 / 02 / 2026, pp. 64 / 93 48 / 68 PBO n=46 Upadacitinib and 6 mg QD N=49 Upadacitinib and 11 mg QD N=47 Upadacitinib and 22 mg QD N=43 TOTAL N=185 Fitzpatrick, n (%) 11 (23.9) 13 (26.5) 15 (31.9) 14 (32.6) 53 (28.6) • Type I 17 (37.0) 17 (34.7) 19 (40.4) 17 (39.5) 70 (37.8) • Type II 9 (19.6) 11 (22.4) 9 (19.1) 9 (20.9) 38 (20.5) • Type III 4 (8.7) 5 (10.2) 2 (4.3) 2 (4.7) 13 (7.0) • Type IV • Type V • Type VI 2 (4.3) 2 (4.1) 1 (2.1) 0 5 (2.7) Table 3. Disease characteristics at baseline PBO n=46 Upadacitinib e 6 mg QD N=49 Upadacitinib e 11 mg QD N=47 Upadacitinib e 22 mg QD N=43 TOTAL N=185 Active vitiligo status, n (%): Active Stable 34 (73.9) 12 (26.1) 33 (67.3) 16 (32.7) 32 (68.1) 15 (31.9) 32 (74.4) 11 (25.6) 131 (70.8) 54 (29.2) Duration of vitiligo disease since symptom onset (years), mean (SD) 20.4 (13.8) 18.3 (12.0) 19.8 (13.6) 16.3 (13.3) 18.8 (13.2) Disease duration Vitiligo since diagnosis (years), mean (SD) 18.5 (13.8) 16.0 (11.4) 17.9 (13.9) 14.7 (13.7) 16.8 (13.2) F-VASI, mean (SD) 1.0 (0.6) 1.2 (0.8) 1.0 (0.6) 1.2 (0.7) 1.1 (0.7) T-VASI, mean (SD) 21.0 (17.0) 21.0 (16.0) 22.3 (18.2) 21.8 (15.9) 21.5 (16.7) VES, mean (SD) 16.9 (16.5) 18.8 (18.1) 17.7 (15.3) 20.2 (16.9) 18.4 (16.7) VitiQoL score, mean (SD) 42.4 (21.9) 39.5 (22.7) 40 (22.6) 45.9 (22.6) 41.8 (22.4) History of symptoms related to vitiligo, n (%) Increased sensitivity to sun / sunburns Itching in vitiligo lesions Pain in lesions 22 (47,8) 15 (32,6) 4 (8,7) 30 (61,2) 17 (34,7) 7 (14,3) 29 (61,7) 10 (21,3) 4 (8,5) 27 (62,8) 10 (23,3) 3 (7,0) 108 (58,4) 52 (28,1) 18 (9,7) Petition 870260018663, dated 27 / 02 / 2026, pp. 65 / 93 49 / 68 PBO n=46 Upadacitinib 6 mg QD N=49 Upadacitinib 11 mg QD N=47 Upadacitinib 22 mg QD N=43 TOTAL N=185 vitiligo Previous topical therapy (TCS / TCI), n (%) 22 (47.8) 19 (38.8) 20 (42.6) 18 (41.9) 79 (42.7) Previous phototherapy, n (%) 12 (26.1) 4 (8.2) 9 (19.1) 10 (23.3) 35 (18.9) Individual disposition

[0250] The individual's disposition in Period 1 and Period 2 is provided for each treatment group in Tables 4 and 5, respectively. With reference to Tables 4 and 5, the majority of randomized patients completed the study, with few discontinuations observed. Table 4. Individual disposition - period 1 PBO Upadacitinib 6 mg QD Upadacitinib 11 mg QD Upadacitinib 22 mg QD Randomized N=46 N=49 N=47 N=43 Treated 46 (100) 49 (100) 47 (100) 43 (100) Study drug completed in period 1 43 (93.5) 45 (91.8) 45 (95.7) 33 (76.7) Study drug discontinued prematurely 3 (6.5) 4 (8.2) 2 (4.3) 10 (23.3) Treatment withdrawal by the individual 2 (4.3) 1 (2.0) 1 (2.1) 5c (11.6) Adverse event 0 1 (2.0) 0 4d (9.3) Loss to follow-up 0 2 (4,1) 1 (2,1) 0 Progressive disease 1 (2,2) 0 0 1 (2,3) Lack of effectiveness 0 0 0 0 COVID-19 infection 0 0 0 0 Table 5. Individual disposition - period 2 PBO / Upadacitinib and 11 mg QD PBO / Upadacitinib and 22 mg QD Upadacitinib and 6 mg QD Upadacitinib and 11 mg QD Upadacitinib and 22 mg QD Entered N=20 N=22 N=45 N=45 N=33 Treated 20 (100) 22 (100) 45 (100) 45 (100) 33 (100) Petition 870260018663, dated 27 / 02 / 2026, pp. 66 / 93 50 / 68 PBO / Upadacitinib and 11 mg QD PBO / Upadacitinib and 22 mg QD Upadacitinib and 6 mg QD Upadacitinib and 11 mg QD Upadacitinib and 22 mg QD Study drug in progress in Period 2 5 (25) 10 (45.5) 20 (44.4) 18 (40) 13 (39.4) Study drug completed in Period 2 14 (70) 11 (50) 21 (46.7) 21 (46.7) 17 (51.5) Study drug prematurely discontinued 1 (5) 1 (4.5) 4 (8.9) 6 (13.3) 3 (9.1) Loss to follow-up 0 0 1 (2.2) 4 (8.9) 1 (3) Withdrawal Treatment by the individual 0 1 (4.5) 2 (4.4) 1 (2.2) 0 Adverse event 1 (5) 0 1 (2.2) 1 (2.2) 1 (3) Progressive disease 0 0 0 0 1 (3) Lack of efficacy 0 0 0 0 0 COVID-19 infection 0 0 0 0 0 Effectiveness:

[0251] Overall, upadacitinib 11 mg and 22 mg met the primary endpoint (% change from baseline in F-VASI at Week 24) and also met most secondary endpoints (F-VASI 75, F-VASI 50, % change from baseline in T-VASI). Overall, consistency of response to upadacitinib was observed in pre-specified subgroups (active and stable, T-VASI < 10 and > 10). Efficacy data are shown in Figures 2 to 5A / B and Tables 6 to 8. With reference to Table 6, upadacitinib 11 mg did not reach the T-VASI 50 secondary trial endpoint at week 24. Notably, the proportion of subjects who achieved an F-VASI 75 and a T-VASI 50 continued to increase through Week 52 with all doses of upadacitinib (for subjects who had the opportunity to reach Week 52). Table 6. Summary of the proportion of patients who reached the endpoints of Petition 870260018663, dated 27 / 02 / 2026, p. 67 / 93 51 / 68 test Test endpoints (All at Week 24) PBO N = 46 Upadacitinib 6 MG QD N = 49 Upadacitinib 11 MG QD N = 47 Upadacitinib 22 MG QD N = 43 Primary test endpoint: Percentage of CFB in F-VASI; LSMEAN (SE) N=43 -14.36 (5,307) N=45 -21.96 (5,162) Δ=-7.60; p=0.304 N=43 -35.63 (5,297) Δ=-21.27; p=0.005*** N=33 -33.96 (5,793) Δ=-19.60; p=0.013** Secondary test endpoints: T-VASI 50; n (%) 1 (2.2) 3 (6.1) Δ=3.7; p=0.340 3 (6.4) Δ=3.8; p=0.358 5 (11.6) Δ=9.1; p=0.027** F-VASI 75; n (%) 1 (2.2) 4 (8.2) Δ=6.9; p=0.100* 9 (19.1) Δ=17.8; p=0.002*** 6 (14.0) Δ=11.7; p=0.026** F-VASI 50; n (%) 5 (10.9) 8 (16.3) Δ=6.6; p=0.327 18 (38.3) Δ=29.3; p<0.001**** 17 (39.5) Δ=28.7; p<0.001**** Percentage of CFB in T-VASI; LSMEAN (SE) N=43 -6.42 (3.423) N=45 -13.87 (3.332) Δ=-7.45; p=0.120 N=43 -17.26 (3.414) Δ=-10.84; p=0.026** N=33 -20.69 (3.731) Δ=-14.27; p=0.005*** CFB in total VitiQoL score; LSMEAN (SE) N=40 -5.5 (2.41) N=44 -7.5 (2.27) Δ=-1.9; p=0.545 N=44 -3.7 (2.30) Δ=1.9;p=0.565 N=34 -6.6 (2.56) Δ=-1.1; p=0.754;

[0252] Regarding the Physician Global Impression of Change (PhGIC) and According to the Patient Global Impression of Change (PaGIC), patients achieved greater efficacy with upadacitinib 11 and 22 mg versus placebo (Table 7). Table 7. Proportion of patients who achieved the additional test endpoints. Final test scores (All in Week 24) PBO N = 46 Upadacitinib and 6 MG QD N = 49 Upadacitinib and 11 MG QD N = 47 Upadacitinib and 22 MG QD N = 43 % of achieving much better or somewhat better in PhGIC, n (%) N=46 11 (23.9%) N=49 21 (42.9%) Δ=18% p=0.043 N=47 28 (59.6%) Δ=37.8% p<0.001 N=43 24 (55.8%) Δ=32% p<0.001 % of achieving much better or somewhat better 9 (19.6%) 17 (34.7%) Δ=14.3% 26 (55.3%) Δ=38.5% 26 (60.5%) Δ=41.1% Petition 870260018663, dated 27 / 02 / 2026, pp. 68 / 93 52 / 68 Final test scores (All in Week 24) PBO N = 46 Upadacitinib and 6 mg QD N = 49 Upadacitinib and 11 mg QD N = 47 Upadacitinib and 22 mg QD N = 43 slightly better on PaGIC, n (%) p=0.081 p<0.001 p=<0.001 in week 24 Table 8. Reported results Upadacitinib and 6 mg QD (N=49) Upadacitinib and 11 mg QD (N=47) Upadacitinib and 22 mg QD (N=43) PBO (N=46) VitiQoLa Mean LS change, % (SE) pb value -7.5 (2.3) .545 -3.7 (2.3) .565 -6.6 (2.6) .754 -5.5 (2.4) VNS score of 4 or 5c Respondents, n (%) 0 0 5 (11.6) 0 pb value 0.005 DLQId Mean LS change, % (SE) -1.4 (0.5) -1.2 (0.5) -2.2 (0.5) -0.6 (0.5) pb value 0.212 0.361 0.027 Score of PaGIC-V of 1 or 2e Respondents, n (%) 17 (34.7) 26 (55.3) 26 (60.5) 9 (19.6) pb value 0.081 <.001 <.001 Anxiety in HADSf Mean LS change, % (SE) -0.7 (0.4) 0.0 (0.4) -0.3 (0.4) 0.3 (0.4) pb value .063 .670 .343 Depression in HADS f Mean LS change, % (SE) 0.2 (0.3) -0.3 (0.3) -0.1(0.4) 0.4(0.3) pb value .638 .150 .352 DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale; PaGIC-V, Patient Global Impression of Change - Vitiligo; PBO, placebo; UPA, upadacitinib; VitiQoL, vitiligo quality of life; VNS, Vitiligo Perception Scale. Change in VitiQoL from baseline. Number of patients: UPA 6 mg, 44; UPA 11 mg, 44; UPA 22 mg, 34; placebo, 40. bP-values ​​are vs. PBO and are nominal and not adjusted for multiplicity. cVNS response was defined as a score of 4 (much less noticeable) or 5 (no longer noticeable). dChange in DLQI from baseline. Number of patients: UPA 6 mg, 43; UPA 11 mg, 42; UPA 22 mg, 35; placebo 38. The PaGiC-V response was defined as a score of 1 (much better) or 2 (somewhat better). Petition 870260018663, dated 27 / 02 / 2026, pp. 69 / 93 53 / 68 Upadacitinib 6 mg QD (N=49) Upadacitinib 11 mg QD (N=47) Upadacitinib 22 mg QD (N=43) PBO (N=46) fHADS anxiety score and changes in HADS depression score from baseline. Number of patients: UPA 6 mg, 44; UPA 11 mg 45; UPA 22 mg, 34; placebo 40.

[0253] Preliminary 3D imaging data support the greater efficacy of upadacitinib 11 and 22 mg versus placebo (see Example 3). Specifically, patients who received upadacitinib 11 and 22 mg demonstrated a greater percentage change from baseline in the vitiligo extent score (VES) as assessed by 3D imaging. Biomarkers

[0254] Reductions from baseline were observed in inflammatory chemotactic proteins (CXCL9 and 10) and T-cell activation markers (IL12B and TNFSF9), indicating an effect on type 1 inflammation (data not shown). The reductions observed in type 1 inflammation biomarkers suggest that maximum inhibition was achieved at the 11 mg dose. Biomarker reductions were observed as early as week 2 and were maintained through week 24, with similar effects observed across all upadacitinib doses, although a slightly smaller effect was observed in the 6 mg treatment group. For CXCL10, levels were reduced to those in healthy volunteers at week 2 in all dose groups. Overall, serum biomarker data support the greater efficacy of UPA 11 mg and 22 mg vs. placebo. No difference was evident for active vs. stable subjects. Example 2: Exposure-response analysis for effectiveness at week 24

[0255] An analysis of drug exposure vs. response was performed using the data from Example 1. Regression models were developed for change from baseline in F-VASI, change from baseline in T-VASI, FVASI 75, and T-VASI 50 at Week 24. Linear and nonlinear regression models were Petition 870260018663, dated 27 / 02 / 2026, pp. 70 / 93 54 / 68 were evaluated for continuous endpoints (change from baseline in F-VASI and T-VASI). A linear, logarithmic, treatment effect, and Emax model was evaluated for categorical endpoints (F-VASI 75 and T-VASI 50). Stratification factors from the Phase 2 study were included in all evaluated models. Final models for each endpoint were selected based on the Akaike Information Criterion and visual predictive checks.

[0256] Preliminary exposure-response analyses for efficacy at Week 24, based on Period 1 data, showed clear exposure-response relationships for change from baseline in F-VASI, change from baseline in T-VASI, F-VASI 75, and T-VASI 50, with an increase in response with increasing mean plasma exposures of upadacitinib (Cmean; Figures 6A and 6B). These relationships were described using regression models for continuous time endpoints (change from baseline in F-VASI and T-VASI) and logistic regression models for categorical test endpoints (F-VASI 75 and T-VASI 50).A logarithmic model was selected for change from baseline in F-VASI, F-VASI 75, and T-VASI 50, and a linear model was selected for change from baseline in T-VASI, where the exposure-response relationships for change from baseline in F-VASI, change from baseline in T-VASI, and F-VASI 75 were significant (P < 0.05). The exposure-response relationship for T-VASI 50 was not significant, likely due to the limited number of responders for that endpoint of the test.

[0257] Simulations were conducted for 1000 trials with 400 subjects in each trial for placebo, 6 mg QD, 11 mg QD, 15 mg QD, 22 mg QD, and 30 mg QD regimens, and predicted response rates are provided in Figures 7A and 7B. With reference to Figure 7A / B, the simulations predict that upadacitinib 22 mg QD will provide 3 to 5% greater efficacy than the 11 mg dose for F- and T-VASI at week 24, and upadacitinib 15 mg or 30 mg QD will provide efficacy benefit. Petition 870260018663, dated 27 / 02 / 2026, pp. 71 / 93 55 / 68 additional limited dose compared to upadacitinib 11 mg or 22 mg QD, respectively.

[0258] Preliminary exposure-response analyses for all individuals who completed Week 52 were conducted for change from baseline in F-VASI and change from baseline in T-VASI. Limited data were available for Week 52. A logarithmic model better described these exposure-response relationships at Week 36 and indicated that efficacy appears to approach a plateau in plasma exposures associated with the 15 mg QD regimen (Figures 8A and 8B). Exposure-response relationships were shallower for change from baseline in F-VASI and T-VASI at Week 52 compared to Week 24. Therefore, a dose higher than 15 mg is not predicted to provide significant additional efficacy benefit at Week 52.

[0259] Based on all available data (pharmacokinetics, CFB TVASI and CFB F-VASI) at all available visits up to Week 52, a longitudinal model was developed. The model-predicted efficacy was generally consistent with the observed data over 52 weeks of treatment and shows an increase in treatment effect over time (Figures 9A and 9B). With reference to Figures 9A and 9B, the model-predicted effect sizes for upadacitinib 15 mg at Week 36 are estimated to be: F-VASI 75: 23.2% (15.9% to 30.4%) and TVASI 50: 17.4% (10.9% to 23.9%).

[0260] Upadacitinib 15 mg QD is approved for the treatment of adults with RA, PsA, AD, AS, nr-axSpA, and UC (maintenance treatment) and in adolescents with AD. Furthermore, this dosing regimen has a robust and well-characterized safety profile across the different indications. The Phase 2b Example 1 Study evaluated upadacitinib doses of 6 mg QD, 11 mg QD, and 22 mg QD in a placebo-controlled manner over 24 weeks. As detailed earlier in this document, the dose-response and biomarker results from this Phase 2b study demonstrate the efficacy, safety, and pharmacodynamic response of 11 mg. Petition 870260018663, dated 27 / 02 / 2026, pp. 72 / 93 56 / 68 QD and higher doses in vitiligo.

[0261] As described above, exposure-response analyses from the Phase 2b study demonstrated that efficacy in vitiligo approaches a plateau at plasma exposures associated with 15 mg QD. Although the proposed Phase 3 dosing regimen of 15 mg QD (Example 4) was not studied in the Phase 2 study of Example 1, it is estimated to provide plasma exposures that are within the range of plasma exposures that were evaluated in the Phase 2b study of Example 1. Example 3. Clinical validation of 3D digital imaging.

[0262] In the Example 2 clinical study, 3D imaging data were obtained and analyzed to aid in evaluating treatment efficacy. Specifically, multiple stereoscopic images were captured by a proprietary 3D optical scanner for a subset of patients in the referenced study. The data capture and vitiligo area determination procedures using the 3D platform were as follows: 1. The individual was scanned, capturing raw 2D color images with real-time feedback to generate a low-resolution 3D grayscale model. 2. Full-resolution color model generated and uploaded to the cloud. 3. Web application opened by the investigator, who manually selected the boundary for each region of the face. 4. The area of ​​vitiligo detected was measured and the results reported.

[0263] Two objectives were predefined for the clinical validation of 3D digital imaging output in vitiligo patients in the study: to determine the clinical validity of the 3D imaging platform in the vitiligo population by correlating 3D facial vitiligo measurements with two established clinical vitiligo measures, F-VASI, FPhGVA, and Patient Global Assessment of Vitiligo - Face; and to evaluate whether vitiligo area measurement by the 3D imaging platform can be used to determine a clinically significant change after upadacitinib therapy, supporting the measurement Petition 870260018663, dated 27 / 02 / 2026, pp. 73 / 93 57 / 68 of the facial vitiligo area based on a 3D imaging platform to determine the efficacy of upadacitinib in patients with vitiligo.

[0264] To achieve these objectives, twenty-seven individuals were enrolled in the 3D imaging substudy at 6 clinical sites. Twenty-one individuals had high-quality 3D images available at Week 24 for analysis. Individuals enrolled in the 3D digital imaging substudy were randomized according to the main protocol. Demographic data, including Fitzpatrick skin types and baseline disease characteristics in the 3D imaging substudy, are provided in Table 9. With reference to Table 9, demographic data were generally consistent with the overall study population. Table 9. Individual demographic data and baseline disease characteristics in the 3D imaging substudy. PBO N = 4 Upadacitinib 6 mg QD N = 9 Upadacitinib 11 mg QD N = 7 Upadacitinib 22 mg QD N = 7 TOTAL N = 27 Female, n (%) 2 (50.0) 5 (55.6) 5 (71.4) 4 (57.1) 16 (59.3) Mean age (years) (SD) 50.3 (7.32) 43.7 (11.7) 49.1 (11.42) 39.4 (13.45) 45.0 (12.45) Age range < 50 years, n (%) 2 (50.0) 6 (66.7) 3 (42.9) 5 (71.4) 16 (59.3) Race, n (%) White 2 (100) 4 (50.0) 6 (85.7) 5 (71.4) 17 (70.8) Black / African American 0 0 0 0 0 BMI (kg / m2), mean (SD) 24.76 (3.021) 25.06 (3.040) 27.19 (5.420) 29.16 (6.139) 26.63 (4,750) Fitzpatrick skin types, n (%) Type I 0 0 0 0 0 Type II 1 (25.0) 3 (33.3) 3 (42.9) 4 (57.1) 11 (40.7) Type III 1 (25.0) 2 (22.2) 3 (42.9) 1 (14.3) 7 (25.9) Type IV 2 (50.0) 2 (22.2) 1 (14.3) 2 (28.6) 7 (25.9) Type V 0 2 (22.2) 0 0 2 (7.4) Type VI 0 0 0 0 0 Active vitiligo status, n (%) Active 3 (75.0) 9 (100) 4 (57.1) 5 (71.4) 21 (77.8) Stable 1 (25.0) 0 3 (42.9) 2 (28.6) 6 (22.2) Duration of vitiligo disease since symptom onset (years), 40.1 (9.26) 17.5 (8,40) 18.9 (12.47) 16.2 (10.30) 20.9 (12.64) Petition 870260018663, dated 27 / 02 / 2026, pp. 74 / 93 58 / 68 PBO N = 4 Upadacitinib and 6 mg QD N = 9 Upadacitinib and 11 mg QD N = 7 Upadacitinib and 22 mg QD N = 7 TOTAL N = 27 mean (SD) Duration of vitiligo disease since diagnosis (years), mean (SD) 34.5 (12.44) 16.4 (8.38) 17.2 (11.84) 15.9 (10.66) 19.1 (11.87) F-VASI, mean (SD) 1.313 (0.7327) 0.824 (0.3796) 0.924 (0.5534) 1.577 (0.7472) 1.118 (0.6390) T-VASI, mean (SD) 12.545 (4.5618) 20,729 (10,0861) 17,066 (15,1678) 25,501 (16,4254) 19,804 (12,9698) BMI = Body Mass Index; F-VASI = Variable Area Score Index Facial Vitiligo; PBO = placebo; QD = once daily; SD = standard deviation; TCI = topical calcineurin; TCS = topical corticosteroids; T-VASI = Total Area Score Index of Vitiligo; UPA = upadacitinib; VitiQoL = vitiligo quality of life.

[0265] The quality and integrity of each scan were assessed by visual inspection of the resulting 3D image by the technician and / or investigator, using Wood's Lamp visualization to define a baseline threshold, defined as the intensity value used to distinguish which 3D pixels within the image belong to the vitiligo area or the normal skin area. The baseline threshold value determined by the investigator remained constant and applied to all post-baseline 3D images during the treatment period to reflect changes in pigmentation. Each 3D image included 10 predefined anatomical regions of the face: forehead, left eye, right eye, left lateral cheek / temple, left mid-cheek, nose, right mid-cheek, right lateral cheek / temple, upper lip, and chin. Results are presented as the sum of the vitiligo area measurement (cm2) in all anatomical regions of the face.A representative individual from the study at baseline and at week 24 who was randomized to the upadacitinib 22 mg QD group is provided in Table 10. With reference to Table 10, the 3D imaging results of the whole face show a percentage decrease in the area of ​​vitiligo (-27.20%) near the... Petition 870260018663, dated 27 / 02 / 2026, pp. 75 / 93 59 / 68 which was observed for F-VASI (-24.62%). Table 10. 3D imaging versus F-VASI Treatment Skin type according to Fitzpatrick 3D Imaging Cherry (Vitiligo area; cm2) F-VASI Upadacitinib 22 mg Type III (sometimes burns, tans moderately) Baseline Week 24 % change Baseline Week 24 % change 215.84 157.13 -27.2 1.3 0.98 -24.62

[0266] Due to limited sites (N = 6) involved in the 3D imaging substudy, investigators were only able to recruit 2 patients with Fitzpatrick skin types V and were unable to recruit patients with Fitzpatrick skin types I and VI. In the Example 2 study, approximately 30% of individuals had Fitzpatrick skin types IV, V, or VI. Once data from more patients are available, analyses are planned to determine whether Fitzpatrick skin type has an impact on 3D imaging results and correlation with other clinical measures.

[0267] The correlation between 3D imaging measurements and F-VASI was performed. A high correlation (R = 0.865, P < 0.001) was observed between the vitiligo area measured by 3D imaging versus F-VASI at baseline. A moderate correlation (R = 0.56, P = 0.007) was observed in the percentage change from baseline for 3D imaging versus percentage change in F-VASI at Week 24. The trend in % change from baseline is reflected in both measurements with treatment. Although a good correlation was observed between 3D imaging and F-VASI based on the % change from baseline to Week 24, some discrepancy was also observed. Specifically, although only 3 individuals on placebo were included in the 3D imaging substudy, there was a large difference in the assessment of individuals on placebo between the 3D imaging versus F-VASI measurements. The individual values ​​for the placebo group are presented in Table 11. Petition 870260018663, dated 27 / 02 / 2026, pp. 76 / 93 60 / 68 Table 11. Individuals receiving placebo in the 3D imaging substudy. Fitzpatrick Skin Type 3D Imaging of Vitiligo Area (cm2) F-VASI Baseline Week at 24% CHG Baseline Week at 24% CHG Type II - burns easily, tans minimally 123.03 89.81 -27.00 2.2 1.98 -10.00 Type IV - burns minimally, tans easily 21.24 20.95 -1.40 0.8 0.45 -43.75 Type IV - burns minimally, tans easily 50.18 72.16 43.80 0.63 0.27 -57.14 CHG = alteration; F-VASI = Facial Vitiligo Area Score Index; WK = Week.

[0268] A 3D image highlighting the vitiligo area in the left eye was evaluated and compared with F-VASI. The largest percentage change measured between 3D imaging versus F-VASI was: F-VASI, 3D: 43.80 versus F-VASI: -57.14. This finding suggests that 3D imaging not only provides visually verifiable images of vitiligo but also offers better accuracy and objectivity compared to F-VASI, potentially reducing the placebo effect. A similar relationship (R = 0.53, P < 0.001) was observed in the moderate correlation of vitiligo area by 3D imaging versus the 5-point categorical F-PhGVA. All time points from baseline to Week 24 were included to ensure adequate samples for evaluation of this categorical endpoint test.Taken together, the correlations of 3D digital imaging with established clinical assessments, F-VASI and F-PhGVA, at baseline and post-treatment, support the clinical validity of 3D digital imaging technology for the evaluation of facial vitiligo. The correlation of 3D imaging versus 5-point categorical F-PaGVA resulted in a lower correlation (R = 0.29, P = 0.004), which was similar to... Petition 870260018663, dated 27 / 02 / 2026, pp. 77 / 93 61 / 68 weaker associations of patient assessments with VASI scores.

[0269] The percent change from baseline in facial vitiligo area at week 24 as measured by 3D imaging is summarized in Table 12. At Week 24, upadacitinib doses of 6 mg QD, 11 mg QD, and 22 mg QD resulted in percent reductions in facial vitiligo area from baseline of 15.2%, 34.96%, and 23%, respectively, as measured by 3D imaging. The moderate to high correlation with F-VASI and dose-response results, which are consistent with the primary phase 2 analysis, suggest that 3D can measure clinically significant changes. The treatment effect size (Cohen's d) measured by 3D imaging versus F-VASI is compared and summarized in Table 13. Although the sample size was relatively small, the 3D imaging results show a strong effect size (> 0.8) with the 11 mg QD and 22 mg QD doses, which is larger than that of F-VASI.Figure 10A provides the percent change from baseline in vitiligo area by 3D imaging per treatment group at Week 24, and Figure 10B provides the percent change in F-VASI per treatment group at Week 24 (individual patients and mean values ​​(N = 21)). Table 12. Percentage change at week 24 from baseline in the area of ​​facial vitiligo by 3D imaging Percentage change in facial vitiligo area by 3D imaging at week 24. Treatment N Mean (SD) Median Min., max. [95% CI] Placebo 3 5.14 (35.85) -1.38 [-27.00, 43.80] [-83.9, 94.2] 6 mg of UPA QD 7 -15.20 (44.94) -9.85 [-96.02, 54.51] [-56.8, 26.4] 11 mg of UPA QD 6 -34.96 (21.52) -37.38 [-61.35, -7.66] [-57.5, -12.4] 22 mg of UPA QD 5 -23.00 (15.11) -27.2 [-40.97, -5.86] [-41.8, -4.2] CI = confidence interval; Max = maximum; Min = minimum; QD = once daily; SD = standard deviation; UPA = updacitinib Petition 870260018663, dated 27 / 02 / 2026, pp. 78 / 93 62 / 68 Table 13. Treatment effect size (Cohen's d) measured by 3D imaging versus F-VASI at week 24___________________________ Week 24 Placebo (N = 3) vs UPA 6 mg (N = 7) Placebo (N = 3) vs UPA 11 mg (N = 6) Placebo (N = 3) vs UPA 22 mg (N = 5) Cohen's d of 3D imaging 0.50 1.36 1.02 Cohen's d of FVASI 0.76 0.13 0.61 F-VASI = Facial Vitiligo Area Score Index; UPA = upadacitinib Example 4: A 36-week double-blind, placebo-controlled Phase 3 study

[0270] This is a 36-week, double-blind, single-dose, placebo-controlled Phase 3 clinical trial in adult patients with non-segmental vitiligo. The study encompasses two studies. The first study is a 36-week study with 15 mg of upadacitinib versus placebo. The second study is a 12-week study of 15 mg of upadacitinib versus placebo, followed by adjuvant ultraviolet (UVB) phototherapy treatment for 24 weeks (placebo versus 15 mg of upadacitinib). Each of studies 1 and 2 will be followed by a 104-week extension period. A study scheme is shown in Figure 11.

[0271] The selection of the 15 mg QD dose is based on the following: • The 11 mg QD and 22 mg QD regimens met the primary trial endpoint as well as most key secondary trial endpoints at Week 24, demonstrating greater efficacy of upadacitinib compared to placebo with a nominal P-value < 0.05. Both the 11 mg and 22 mg QD regimens showed greater efficacy compared to placebo for the primary trial endpoint (percent change from baseline in F-VASI), F-VASI 50, F-VASI 75, and percentage change from baseline in T-VASI. Only the 22 mg QD dosing regimen showed greater efficacy compared to placebo for T-VASI 50. • Available biomarker data from the Phase 2b study (Example Petition 870260018663, dated 27 / 02 / 2026, pp. 79 / 93 63 / 68 1) showed reductions in circulating type 1 inflammation biomarkers to healthy volunteer levels, suggesting that maximum inhibition is achieved at the 11 mg dose. Biomarker reductions were observed as early as Week 2 and were maintained through Week 24. Similar effects were observed between the 11 mg and 22 mg dose levels, with a slightly smaller reduction observed in the 6 mg treatment group. Inclusion / exclusion criteria For Study 1 • Adult and adolescent (male and female) > 12 years of age • Leukotrichia in < 33% of the affected area • No segmental or localized vitiligo • No exposure to any topical JAK inhibitor for any indication within 12 weeks of the initial visit For Study 2 • Adults only • There must be no lack of response to previous phototherapy, including narrowband UV-B (nbUVB) or equivalent laser therapy • There must be no contraindications to nbUVB phototherapy: • Photosensitive disorder, including but not limited to SLE, dermatomyositis • Use of photosensitizing medications • Photoinduced epilepsy • Cataracts, aphakia • Genetic skin cancer syndrome, dysplastic nevus syndrome • History of treatment with arsenic or ionizing radiation Final points of the effectiveness test. Primary: • Achievement of F-VASI 75 in week 36 Petition 870260018663, dated 27 / 02 / 2026, pp. 80 / 93 64 / 68 Secondary graded (at week 36) • Achievement of T-VASI 50 • Achievement of F-VASI 50 • Achievement of F-VASI 90 • Patient-Assessed Global Impression of Change regarding Vitiligo (PaGIC-V) • Vitiligo perception scale (VNS) • Halt progression at Week 12 (phototherapy study only) Additional test endpoints: • Vitiligo extent score (VES) • Vitiligo quality of life (VitiQoL) • Hospital Anxiety and Depression Scale (HADS) • Dermatology Life Quality Index (DLQI) • Global Measures of Disease Severity • Halting progression (depigmentation) • Time to onset of repigmentation • Changes in itching or burning sensation • Skin color correlation Example 5: Immediate-release liquid formulation of upadacitinib

[0272] For pediatric use, an oral solution was developed to improve acceptability (palatability and swallowability), stability, and manufacturability. Specifically, a stable oral pharmaceutical solution of upadacitinib at 1 mg / ml and 0.5 mg / ml was prepared. Upadacitinib has good solubility at low pH (shown in Table 14). Therefore, low pH buffers such as citrate, phosphate, tartrate, and formate are suitable for preparing the oral solution. Buffers with higher pH ranges, such as succinate and acetate, are also suitable (see Example 6), but will result in a suspension. Petition 870260018663, dated 27 / 02 / 2026, pp. 81 / 93 65 / 68 oral. Citrate buffer was selected because it has a favorable pKa (~3.1), which is close to the final pH of the oral solution. Consequently, a formulation was developed based on the solubility of upadacitinib in liquid with added citric acid and sodium citrate to completely dissolve upadacitinib.

[0273] Upadacitinib has a strong bitterness above concentrations of 0.1 mg / ml. An acceptable and palatable formulation has a bitterness intensity scale value below 1.0. Therefore, a sweetener, flavor modifier or masking agent, and flavoring agent can mitigate the bitter taste of upadacitinib. Sweeteners or combinations of sweeteners, such as acesulfame potassium, sodium saccharin, sucralose, neotame, sucrose, maltitol, and xylitol are suitable for this oral solution. Flavor modifiers, such as sodium chloride, citric acid, and monoammonium glycyrrhizate, are also suitable for this oral solution. Flavoring agents such as cherry, orange, bubblegum, strawberry, and mango can increase the acceptability of the formulation.

[0274] Upadacitinib oral solution contains water and sweetener, which are potential causes of microbial growth. Upadacitinib oral solution is also a multidose formulation. Therefore, a preservative is added to the formulation to prevent microbial proliferation. Preservatives such as sodium benzoate and propylparaben are suitable based on the final pH of the oral solution. Other preservatives, such as sodium metabisulfite, benzoic acid, hydroxyparaben, potassium sorbate, and hydroxyparabenzoic acid may also be used based on the final pH of the oral solution or suspension.

[0275] Upadacitinib 1 mg / ml oral solution C contained citric acid, sodium citrate, sucralose, sodium benzoate, and water. The 1 mg / ml oral solution was clear and colorless to light yellow.

[0276] The composition of certain oral solutions of 1 mg / ml and 0.5 mg / ml is shown in Table 15. Petition 870260018663, dated 27 / 02 / 2026, pp. 82 / 93 66 / 68 Table 14. Solubility of upadacitinib in different aqueous media at 37°C. Medium pH (Nominal) pH (Final) Solubility (mg / ml) 0.1 N HCl 1.0 2.57 38.4 ± 1.5 50 mM Phosphate 2.01 3.08 10.5 ± 0.1 50 mM Citrate 3.00 3.39 4.48 ± 0.08 50 mM Citrate 4.01 4.16 1.00 ± 0.01 50 mM Citrate 5.03 5.01 0.289 ± 0.006 50 mM Citrate 6.01 5.96 0.196 ± 0.001 50 mM Phosphate 7.02 7.14 0.194 ± 0.001 50 mM Phosphate 8.02 7.99 0.200 ± 0.013 Carbonate 50 mM 9.02 9.11 0.199 ± 0.006 Water 6.02 6.92 0.240 ± 0.004 Simulated Fed-State Bowel Fluid (FeSSIF) 5.01 5.10 0.455 ± 0.006 FeSSIF 6.50 6.58 0.262 ± 0.003 Table 15. Compositions of certain oral solutions of upadacitinib. Clinic A Clinic BC Formulation 1 mg / ml 0.5 mg / ml 1 mg / ml Component Function Quantity (g) Upadacitinib free base Active ingredient 0.100 0.050 0.100 Sodium benzoate Preservative 0.050 0.030 0.030 Anhydrous citric acid pH modifier 0.288 0.213 0.213 Sodium citrate dihydrate Buffer -- 0.116 0.045 Sucralose Sweetener 0.900 0.900 0.900 Purified water Solvent qs to 100 qs to 100 qs to 100 Example 6. Liquid formulation of upadacitinib, immediate-release or extended-release (suspension).

[0277] An immediate-release oral suspension is prepared to accommodate a higher dosage or a higher pH. The buffers, preservatives, and sweeteners listed in Example 4 may be applied to this formulation. Generally, a prolonged-release liquid formulation is prepared to provide prolonged release of upadacitinib for once-daily administration using a rate-release modifier, such as an ion-exchange resin. The forms Petition 870260018663, dated 27 / 02 / 2026, pp. 83 / 93 Liquid pharmaceutical dosage forms 67 / 68 comprise an upadacitinib-ion exchange resin complex. The upadacitinib-ion exchange resin complex comprises upadacitinib or a pharmaceutically acceptable salt thereof linked to an ion exchange resin. Suitable ion exchange resins include, but are not limited to, a sulfonated copolymer comprising styrene and divinylbenzene. In some of these embodiments, the mobile or exchangeable cation is sodium. An exemplary cationic ion exchange resin is AmberLite™ IRP 69 (DuPont). Example 7: Effectiveness Analysis up to Week 52

[0278] This Example provides efficacy data up to week 52 for the Example 1 clinical study. As described above in Example 1, at week 24, upadacitinib reached the primary endpoint of percent change from baseline in the Facial Vitiligo Area Score Index (F-VASI) with doses of 11 mg and 22 mg versus placebo in adults with nonsegmental vitiligo (NSV). One hundred and sixty-six patients (166; 89.7%) continued to the blinded 28-week extension (period two) as described in Example 1. In period two, patients who received upadacitinib during period one continued their respective regimens (upadacitinib 22 mg, N=33; upadacitinib 11 mg, N=45; upadacitinib 6 mg, N=45); Patients who received placebo in period one were pre-assigned to receive upadacitinib 11 mg (N=21) or upadacitinib 22 mg (N=22) in period two.

[0279] Data up to week 52 are provided in Table 16 and Table 17 and Figures 12 through 16D. With reference to Table 16, Table 17 and Figures 12 to 16, at week 52 of the study, the percentage reduction from baseline in F-VASI was numerically greater than the results observed at week 24 for all upadacitinib doses. Furthermore, the response rates observed for F-VASI 75 and T-VASI 50 at week 52 were numerically greater than those at week 24 for all upadacitinib dose groups. Table 16. Data from Week 52 (Intention-to-Treat Population, Petition 870260018663, dated 27 / 02 / 2026, pp. 84 / 93 68 / 68 MMRM / NRI-MI) 6 mg UPA (N=49) 11 mg UPA (N=47) 22 mg UPA (N=43) PBO (N=46) Percentage of CFB in FVASI -52.3 -62.8 -59.2 N / A F-VASI 75 (%) 28.6 51.1 25.6 N / A T-VASI 50 (%) 24.5 31.9 27.9 N / A Table 17. Data from Week 52 (as observed) 6 mg UPA (N=38) 11 mg UPA (N=38) 22 mg UPA (N=29) Percentage of CFB in FVASI -52.7 -64.8 -60.8 F-VASI 75 (%) 36.8 63.2 37.9 T-VASI 50 (%) 31.6 39.5 41.4 Petition 870260018663, dated 27 / 02 / 2026, pages 85 / 93

Claims

1 / 7 CLAIMS 1. Use of upadacitinib CHARACTERIZED by the fact that it is for the preparation of a medicament for the treatment of vitiligo in an adult human patient, wherein upadacitinib is formulated to be administered orally once daily to the patient at a dose of 15 mg of upadacitinib.

2. Use, according to claim 1, CHARACTERIZED in that the patient has non-segmental vitiligo (NSV), in which the NSV is stable, or in which the NSV is active.

3. Use, according to claim 1 or 2, CHARACTERIZED in that the patient has, before starting treatment, a Facial Vitiligo Area Score Index (F-VASI) > 0.5, or in that the patient has, before starting treatment, a Total Vitiligo Area Score Index (T-VASI) > 5.

4. Use, according to any of claims 1 to 3, CHARACTERIZED in that the patient has not received any immunomodulatory biological therapy prior to initiating treatment; or in that the patient has not received any topical JAK inhibitor within 12 weeks of initiating treatment.

5. Use, according to any one of claims 1 to 4, CHARACTERIZED by the fact that the patient presents with leukotrichia in < 33% of an affected area.

6. Use, according to any of claims 1 to 5, CHARACTERIZED by the fact that the patient presents F-VASI 75 at 24 weeks after the first daily administration, or in which the patient presents, at 36 weeks after the first daily administration, one or more of T-VASI 50, T-VASI 75, T-VASI 90, F-VASI 50, F-VASI 90, or in which the patient presents an improvement in the Impression of Change for All on Vitiligo (PaGIC-V) at 36 weeks after the first daily administration, or in which the patient presents a score on the vitiligo perception scale (VNS) of much less noticeable (4) or no longer noticeable Petition 870260018663, dated 27 / 02 / 2026, page. 86 / 93 2 / 7 (5) at 36 weeks after the first daily administration, or where the patient shows an improvement from baseline in the vitiligo extent score (VES) at 36 weeks after the first daily administration,or in which the patient shows an improvement from baseline in VitiQoL at 36 weeks after the first daily administration, or in which the patient has a total Dermatology Life Quality Index (DLQI) score of 0 or 1 at 36 weeks after the first daily administration, or in which the patient shows an improvement from baseline in Hospital Anxiety and Depression Scale (HADS) scores at 36 weeks after the first daily administration, or in which the patient shows an improvement in time to onset of repigmentation compared to a patient not treated with upadacitinib, or in which the patient shows an improvement in itching or burning sensation within 36 weeks after the start of treatment, or in which the patient has a Physician Global Impression of Change in Vitiligo (PhGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the first daily administration,or in which the patient presents a Patient Global Impression of Change in Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) 36 weeks after the first daily administration, or in which the patient presents a Physician Global Assessment of Vitiligo - Face (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration, or in which the patient presents a Physician Global Assessment of Vitiligo Total (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration, or in which the patient presents a Patient Global Assessment of Vitiligo - Face (F-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration,or in which the patient presents a Patient Global Assessment of Vitiligo - Total (T-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) 36 weeks after the first daily administration, or in which the progression of vitiligo is interrupted within 36 weeks after the start of treatment.

7. Use, according to any of claims 1 to 6, CHARACTERIZED in that a reduction from baseline in one or more vitiligo biomarkers is obtained within 36 weeks of treatment initiation.

8. Use, according to claim 7, CHARACTERIZED in that the biomarker is an inflammatory chemotactic protein or a T cell activation marker.

9. Use, according to claim 7 or 8, CHARACTERIZED in that the biomarker is CXCL9, CXCL10, IL12B, TNFSF9 or a combination thereof.

10. Use, according to any one of claims 1 to 9, CHARACTERIZED by the fact that the patient is concomitantly exposed to ultraviolet light.

11. Use of a therapeutically effective amount of upadacitinib CHARACTERIZED by the fact that it is for the preparation of a medicament for the treatment of vitiligo in a pediatric human patient, wherein: if the pediatric patient has a body weight in the range of about 10 kg to less than about 20 kg: (i) upadacitinib is formulated to be administered twice daily at a dose of 3 mg each time (3 mg BID); or (ii) upadacitinib is formulated to be administered twice daily at a dose of 6 mg each time (6 mg BID); if the pediatric patient has a body weight in the range of about 20 kg to less than about 30 kg: (i) upadacitinib is formulated to be administered twice daily Petition 870260018663, dated 27 / 02 / 2026, p. 88 / 93 4 / 7 a dose of 4 mg each (4 mg BID); or (ii) upadacitinib is formulated to be administered twice daily at a dose of 8 mg each (8 mg BID).and if the pediatric patient has a body weight of approximately 30 kg or more: (i) upadacitinib is formulated to be administered twice daily at a dose of 6 mg each time (6 mg BID), (ii) upadacitinib is formulated to be administered twice daily at a dose of 8 mg each time (8 mg BID), or (iii) upadacitinib is formulated to be administered once daily at a dose of 15 mg (15 mg QD).

12. Use, according to claim 11, CHARACTERIZED in that a dose of 3 mg of upadacitinib twice daily, a dose of 4 mg of upadacitinib twice daily, a dose of 6 mg of upadacitinib twice daily, or a dose of 8 mg of upadacitinib twice daily is formulated to be administered to the pediatric patient as a stable oral pharmaceutical solution.

13. Use, according to claim 11 or 12, CHARACTERIZED in that the stable oral pharmaceutical solution comprises upadacitinib, a buffer and / or a pH adjusting agent, a preservative, a sweetener and water, wherein preferably the oral solution comprises upadacitinib at a concentration of about 0.5 mg / ml or about 1 mg / ml.

14. Use, according to any of claims 11 to 13, CHARACTERIZED in that the 15 mg dose of upadacitinib once daily is formulated to be administered to the pediatric patient as a prolonged-release tablet.

15. Use, according to any of claims 11 to 14, CHARACTERIZED by the fact that the pediatric patient presents with non-segmental vitiligo (NSV), in which the NSV is stable, or in which the NSV is active.

16. Use, according to any of claims 11 to 15, CHARACTERIZED by the fact that the pediatric patient has, before starting treatment, a Facial Vitiligo Area Score Index (F-VASI) > 0.5, or that the patient has, before starting treatment, a Total Vitiligo Area Score Index (T-VASI) > 5, or that the pediatric patient has not received any immunomodulatory biological therapy before starting treatment, or that the pediatric patient has not received any topical JAK inhibitor within 12 weeks of starting treatment, or that the pediatric patient has leukotrichia in < 33% of an affected area, or that the pediatric patient has F-VASI 75 at 24 weeks after the first daily administration, or that the pediatric patient has, at 36 weeks after the first daily administration, one or more of T-VASI 50, T-VASI 75, T-VASI 90, F-VASI 50, F-VASI 90,or in which the pediatric patient shows an improvement in the Overall Impression of Change for All on Vitiligo (PaGIC-V) at 36 weeks after the first daily administration, or in which the pediatric patient shows a Vitiligo Perception Scale (VNS) score of much less noticeable (4) or no longer noticeable (5) at 36 weeks after the first daily administration, or in which the pediatric patient shows an improvement from baseline in the Vitiligo Extent Score (VES) at 36 weeks after the first daily administration, or in which the pediatric patient shows an improvement from baseline in VitiQoL at 36 weeks after the first daily administration, or in which the pediatric patient shows a total Dermatology Life Quality Index (DLQI) score of 0 or 1 at 36 weeks after the first daily administration,or in which the pediatric patient shows an improvement from baseline in Hospital Anxiety and Depression Scale (HADS) scores 36 weeks after the first daily administration, or in which the pediatric patient shows an improvement in time to onset Petition 870260018663, dated 27 / 02 / 2026, p. 90 / 93 6 / 7 of repigmentation compared to a patient not treated with upadacitinib, or where the pediatric patient shows an improvement in itching or burning sensation within 36 weeks of starting treatment, or where the pediatric patient shows a Physician Global Impression of Change Vitiligo (PhGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the first daily administration, or where the pediatric patient shows a Patient Global Impression of Change Vitiligo (PaGIC-V) score of much better (1) or somewhat better (2) at 36 weeks after the first daily administration,or in which the pediatric patient presents a Physician Global Assessment of Vitiligo - Face (F-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration, or in which the pediatric patient presents a Physician Global Assessment of Vitiligo - Total (T-PhGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration, or in which the pediatric patient presents a Patient Global Assessment of Vitiligo - Face (F-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration, or in which the pediatric patient presents a Patient Global Assessment of Vitiligo - Total (T-PaGVA) score of no depigmentation (0) or limited extent of depigmentation (1) at 36 weeks after the first daily administration,or in which the progression of vitiligo is halted within 36 weeks of starting treatment.

17. Use, according to any of claims 11 to 16, CHARACTERIZED in that a reduction from baseline in one or more vitiligo biomarkers is obtained within 36 weeks of treatment initiation.

18. Use, according to claim 17, CHARACTERIZED in that the biomarker is an inflammatory chemotactic protein or a marker of T cell activation.

19. Use, according to claim 17 or 18, CHARACTERIZED in that the biomarker is CXCL9, CXCL10, IL12B, TNFSF9 or a combination thereof.

20. Use, according to any of claims 6 to 19, CHARACTERIZED by the fact that the pediatric patient is concomitantly exposed to ultraviolet light.

21. Use, according to any of claims 1 to 5, CHARACTERIZED by the fact that the patient presents T-VASI 50 at 48 weeks after the first daily administration, or that the patient presents F-VASI 75 at 48 weeks after the first daily administration, or that the patient presents T-VASI 50 at 52 weeks after the first daily administration, or that the patient presents F-VASI 75 at 52 weeks after the first daily administration. Petition 870260018663, dated 27 / 02 / 2026, pp. 92 / 93